Pathophysiology and clinical relevance of atrial myopathy

1.

Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, Lorimer MF, Lau DH, Antic NA, Brooks AG, Abhayaratna WP, Kalman JM, Sanders P (2013) Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 310:2050–2060. https://doi.org/10.1001/jama.2013.280521CrossRefPubMed

2.

Acharya T, Tringali S, Bhullar M, Nalbandyan M, Ilineni VK, Carbajal E, Deedwania P (2015) Frequent atrial premature complexes and their association with risk of atrial fibrillation. Am J Cardiol 116:1852–1857. https://doi.org/10.1016/j.amjcard.2015.09.025CrossRefPubMed

3.

Agarwal I, Glazer NL, Barasch E, Biggs ML, Djousse L, Fitzpatrick AL, Gottdiener JS, Ix JH, Kizer JR, Rimm EB, Sicovick DS, Tracy RP, Mukamal KJ (2014) Fibrosis-related biomarkers and incident cardiovascular disease in older adults: the cardiovascular health study. Circ Arrhythm Electrophysiol 7:583–589. https://doi.org/10.1161/CIRCEP.114.001610CrossRefPubMedPubMedCentral

4.

Ahlberg G, Refsgaard L, Lundegaard PR, Andreasen L, Ranthe MF, Linscheid N, Nielsen JB, Melbye M, Haunso S, Sajadieh A, Camp L, Olesen SP, Rasmussen S, Lundby A, Ellinor PT, Holst AG, Svendsen JH, Olesen MS (2018) Rare truncating variants in the sarcomeric protein titin associate with familial and early-onset atrial fibrillation. Nat Commun 9:4316. https://doi.org/10.1038/s41467-018-06618-yCrossRefPubMedPubMedCentral

5.

Al Aloul B, Adabag AS, Can I, Roukoz H, McClintock S, Benditt D, Tholakanahalli V (2009) Electrocardiographic markers of cardioversion success in patients with atrial fibrillation. S Med J 102:885–889. https://doi.org/10.1097/SMJ.0b013e3181afe5efCrossRef

6.

Al Chekakie MO, Akar JG, Wang F, Al Muradi H, Wu J, Santucci P, Varma N, Wilber DJ (2007) The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation. J Cardiovasc Electrophysiol 18:942–946. https://doi.org/10.1111/j.1540-8167.2007.00887.xCrossRefPubMed

7.

Alonso A, Misialek JR, Eckfeldt JH, Selvin E, Coresh J, Chen LY, Soliman EZ, Agarwal SK, Lutsey PL (2014) Circulating fibroblast growth factor-23 and the incidence of atrial fibrillation: the atherosclerosis risk in communities study. J Am Heart Assoc 3:e001082. https://doi.org/10.1161/JAHA.114.001082CrossRefPubMedPubMedCentral

8.

Andersen JH, Andreasen L, Olesen MS (2021) Atrial fibrillation—a complex polygenetic disease. Eur J Hum Genet 29:1051–1060. https://doi.org/10.1038/s41431-020-00784-8CrossRefPubMed

9.

Andrade J, Khairy P, Dobrev D, Nattel S (2014) The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res 114:1453–1468. https://doi.org/10.1161/CIRCRESAHA.114.303211CrossRefPubMed

10.

Anne W, Willems R, Holemans P, Beckers F, Roskams T, Lenaerts I, Ector H, Heidbuchel H (2007) Self-terminating AF depends on electrical remodeling while persistent AF depends on additional structural changes in a rapid atrially paced sheep model. J Mol Cell Cardiol 43:148–158. https://doi.org/10.1016/j.yjmcc.2007.05.010CrossRefPubMed

11.

Anne W, Willems R, Van der Merwe N, Van de Werf F, Ector H, Heidbuchel H (2004) Atrial fibrillation after radiofrequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics. Heart 90:1025–1030. https://doi.org/10.1136/hrt.2003.023069CrossRefPubMedPubMedCentral

12.

Asinger RW, Koehler J, Pearce LA, Zabalgoitia M, Blackshear JL, Fenster PE, Strauss R, Hess D, Pennock GD, Rothbart RM, Halperin JL (1999) Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: II. dense spontaneous echocardiographic contrast (the stroke prevention in atrial fibrillation [SPAF-III] study). J Am Soc Echocardiogr 12:1088–1096. https://doi.org/10.1016/s0894-7317(99)70106-9CrossRefPubMed

13.

Attia ZI, Noseworthy PA, Lopez-Jimenez F, Asirvatham SJ, Deshmukh AJ, Gersh BJ, Carter RE, Yao X, Rabinstein AA, Erickson BJ, Kapa S, Friedman PA (2019) An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction. Lancet 394:861–867. https://doi.org/10.1016/S0140-6736(19)31721-0CrossRefPubMed

14.

Avazzadeh S, McBride S, O’Brien B, Coffey K, Elahi A, O’Halloran M, Soo A, Quinlan LR (2020) Ganglionated plexi ablation for the treatment of atrial fibrillation. J Clin Med. https://doi.org/10.3390/jcm9103081CrossRefPubMedPubMedCentral

15.

Badacz R, Kleczynski P, Legutko J, Zmudka K, Gacon J, Przewlocki T, Kablak-Ziembicka A (2021) Expression of miR-1-3p, miR-16-5p and miR-122-5p as possible risk factors of secondary cardiovascular events. Biomedicines. https://doi.org/10.3390/biomedicines9081055CrossRefPubMedPubMedCentral

16.

Barthelemy O, Beygui F, Vicaut E, Rouanet S, Van Belle E, Baulac C, Degrandsart A, Dallongeville J, Montalescot G, Investigators O (2009) Relation of high concentrations of plasma carboxy-terminal telopeptide of collagen type I with outcome in acute myocardial infarction. Am J Cardiol 104:904–909. https://doi.org/10.1016/j.amjcard.2009.05.029CrossRefPubMed

17.

Begg GA, Karim R, Oesterlein T, Graham LN, Hogarth AJ, Page SP, Pepper CB, Rhode K, Lip GYH, Holden AV, Plein S, Tayebjee MH (2018) Left atrial voltage, circulating biomarkers of fibrosis, and atrial fibrillation ablation. Prospect Cohort Stud PLoS One 13:e0189936. https://doi.org/10.1371/journal.pone.0189936CrossRef

18.

Benito B, Garcia-Elias A, Ois A, Tajes M, Valles E, Ble M, Yanez Bisbe L, Giralt-Steinhauer E, Rodriguez-Campello A, Cladellas Capdevila M, Marti-Almor J, Roquer J, Cuadrado-Godia E (2022) Plasma levels of miRNA-1-3p are associated with subclinical atrial fibrillation in patients with cryptogenic stroke. Rev Esp Cardiol 75:717–726. https://doi.org/10.1016/j.rec.2021.12.001CrossRefPubMed

19.

Benjamin MM, Moulki N, Waqar A, Ravipati H, Schoenecker N, Wilber D, Kinno M, Rabbat M, Sanagala T, Syed MA (2022) Association of left atrial strain by cardiovascular magnetic resonance with recurrence of atrial fibrillation following catheter ablation. J Cardiovasc Magn Reson 24:3. https://doi.org/10.1186/s12968-021-00831-3CrossRefPubMedPubMedCentral

20.

Berg DD, Ruff CT, Morrow DA (2021) Biomarkers for risk assessment in atrial fibrillation. Clin Chem 67:87–95. https://doi.org/10.1093/clinchem/hvaa298CrossRefPubMed

21.

Bertelsen L, Diederichsen SZ, Haugan KJ, Brandes A, Graff C, Krieger D, Kronborg C, Kober L, Hojberg S, Vejlstrup N, Svendsen JH (2020) Left atrial volume and function assessed by cardiac magnetic resonance imaging are markers of subclinical atrial fibrillation as detected by continuous monitoring. Europace 22:724–731. https://doi.org/10.1093/europace/euaa035CrossRefPubMed

22.

Bohne LJ, Johnson D, Rose RA, Wilton SB, Gillis AM (2019) The association between diabetes mellitus and atrial fibrillation: clinical and mechanistic insights. Front Physiol 10:135. https://doi.org/10.3389/fphys.2019.00135CrossRefPubMedPubMedCentral

23.

Bollmann A, Husser D, Mainardi L, Lombardi F, Langley P, Murray A, Rieta JJ, Millet J, Olsson SB, Stridh M, Sornmo L (2006) Analysis of surface electrocardiograms in atrial fibrillation: techniques, research, and clinical applications. Europace 8:911–926. https://doi.org/10.1093/europace/eul113CrossRefPubMed

24.

Boycott HE, Nguyen MN, Vrellaku B, Gehmlich K, Robinson P (2020) Nitric oxide and mechano-electrical transduction in cardiomyocytes. Front Physiol 11:606740. https://doi.org/10.3389/fphys.2020.606740CrossRefPubMedPubMedCentral

25.

Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C, Lau CP, Van Gelder IC, Hohnloser SH, Carlson M, Fain E, Nakamya J, Mairesse GH, Halytska M, Deng WQ, Israel CW, Healey JS, Investigators A (2014) Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation 129:2094–2099. https://doi.org/10.1161/CIRCULATIONAHA.113.007825CrossRefPubMed

26.

Bras PG, Cunha PS, Timoteo AT, Portugal G, Galrinho A, Laranjo S, Cruz MC, Valente B, Rio P, Delgado AS, Paulo M, Bras M, Ferreira RC, Oliveira MM, Branco LM (2023) Evaluation of left atrial strain imaging and integrated backscatter as predictors of recurrence in patients with paroxysmal, persistent, and long-standing persistent atrial fibrillation undergoing catheter ablation. J Interv Card Electrophysiol. https://doi.org/10.1007/s10840-023-01602-zCrossRefPubMed

27.

Bufano G, Radico F, D’Angelo C, Pierfelice F, De Angelis MV, Faustino M, Pierdomenico SD, Gallina S, Renda G (2022) Predictive value of left atrial and ventricular strain for the detection of atrial fibrillation in patients with cryptogenic stroke. Front Cardiovasc Med 9:869076. https://doi.org/10.3389/fcvm.2022.869076CrossRefPubMedPubMedCentral

28.

Cameli M, Lisi M, Righini FM, Massoni A, Natali BM, Focardi M, Tacchini D, Geyer A, Curci V, Di Tommaso C, Lisi G, Maccherini M, Chiavarelli M, Massetti M, Tanganelli P, Mondillo S (2013) Usefulness of atrial deformation analysis to predict left atrial fibrosis and endocardial thickness in patients undergoing mitral valve operations for severe mitral regurgitation secondary to mitral valve prolapse. Am J Cardiol 111:595–601. https://doi.org/10.1016/j.amjcard.2012.10.049CrossRefPubMed

29.

Carnevale R, Nocella C, Schiavon S, Cammisotto V, Cotugno M, Forte M, Valenti V, Marchitti S, Vecchio D, Biondi Zoccai G, Rubattu S, Martinelli O, Pignatelli P, Violi F, Volpe M, Versaci F, Frati L, Frati G, Sciarretta S (2021) Synergistic beneficial effects of natural activators of autophagy on endothelial cells and platelets. Br J Pharmacol. https://doi.org/10.1111/bph.15399CrossRefPubMed

30.

Carver W, Goldsmith EC (2013) Regulation of tissue fibrosis by the biomechanical environment. Biomed Res Int 2013:101979. https://doi.org/10.1155/2013/101979CrossRefPubMedPubMedCentral

31.

Chadda KR, Ajijola OA, Vaseghi M, Shivkumar K, Huang CL, Jeevaratnam K (2018) Ageing, the autonomic nervous system and arrhythmia: from brain to heart. Ageing Res Rev 48:40–50. https://doi.org/10.1016/j.arr.2018.09.005CrossRefPubMed

32.

Chang CJ, Chen YC, Lin YK, Huang JH, Chen SA, Chen YJ (2013) Rivaroxaban modulates electrical and mechanical characteristics of left atrium. J Biomed Sci 20:17. https://doi.org/10.1186/1423-0127-20-17CrossRefPubMedPubMedCentral

33.

Chao TF, Lin YJ, Tsao HM, Chang SL, Lo LW, Hu YF, Tuan TC, Li CH, Chang HY, Wu TJ, Yu WC, Chen SA (2013) Prolonged atrium electromechanical interval is associated with stroke in patients with atrial fibrillation after catheter ablation. J Cardiovasc Electrophysiol 24:375–380. https://doi.org/10.1111/jce.12054CrossRefPubMed

34.

Chao TF, Suenari K, Chang SL, Lin YJ, Lo LW, Hu YF, Tuan TC, Tai CT, Tsao HM, Li CH, Ueng KC, Wu TJ, Chen SA (2010) Atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation associated with diabetes mellitus or impaired fasting glucose. Am J Cardiol 106:1615–1620. https://doi.org/10.1016/j.amjcard.2010.07.038CrossRefPubMed

35.

Chelu MG, King JB, Kholmovski EG, Ma J, Gal P, Marashly Q, AlJuaid MA, Kaur G, Silver MA, Johnson KA, Suksaranjit P, Wilson BD, Han FT, Elvan A, Marrouche NF (2018) Atrial fibrosis by late gadolinium enhancement magnetic resonance imaging and catheter ablation of atrial fibrillation: 5 year follow-up data. J Am Heart Assoc 7:e006313. https://doi.org/10.1161/JAHA.117.006313CrossRefPubMedPubMedCentral

36.

Chen YH, Xu SJ, Bendahhou S, Wang XL, Wang Y, Xu WY, Jin HW, Sun H, Su XY, Zhuang QN, Yang YQ, Li YB, Liu Y, Xu HJ, Li XF, Ma N, Mou CP, Chen Z, Barhanin J, Huang W (2003) KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 299:251–254. https://doi.org/10.1126/science.1077771CrossRefPubMed

37.

Chou CC, Lee HL, Chang PC, Wo HT, Wen MS, Yeh SJ, Lin FC, Hwang YT (2018) Left atrial emptying fraction predicts recurrence of atrial fibrillation after radiofrequency catheter ablation. PLoS ONE 13:e0191196. https://doi.org/10.1371/journal.pone.0191196CrossRefPubMedPubMedCentral

38.

Christophersen IE, Ellinor PT (2016) Genetics of atrial fibrillation: from families to genomes. J Hum Genet 61:61–70. https://doi.org/10.1038/jhg.2015.44CrossRefPubMed

39.

Christophersen IE, Ravn LS, Budtz-Joergensen E, Skytthe A, Haunsoe S, Svendsen JH, Christensen K (2009) Familial aggregation of atrial fibrillation: a study in Danish twins. Circ Arrhythm Electrophysiol 2:378–383. https://doi.org/10.1161/CIRCEP.108.786665CrossRefPubMedPubMedCentral

40.

Christophersen IE, Rienstra M, Roselli C, Yin X, Geelhoed B, Barnard J, Lin H, Arking DE, Smith AV, Albert CM, Chaffin M, Tucker NR, Li M, Klarin D, Bihlmeyer NA, Low SK, Weeke PE, Muller-Nurasyid M, Smith JG, Brody JA, Niemeijer MN, Dorr M, Trompet S, Huffman J, Gustafsson S, Schurmann C, Kleber ME, Lyytikainen LP, Seppala I, Malik R, Horimoto A, Perez M, Sinisalo J, Aeschbacher S, Theriault S, Yao J, Radmanesh F, Weiss S, Teumer A, Choi SH, Weng LC, Clauss S, Deo R, Rader DJ, Shah SH, Sun A, Hopewell JC, Debette S, Chauhan G, Yang Q, Worrall BB, Pare G, Kamatani Y, Hagemeijer YP, Verweij N, Siland JE, Kubo M, Smith JD, Van Wagoner DR, Bis JC, Perz S, Psaty BM, Ridker PM, Magnani JW, Harris TB, Launer LJ, Shoemaker MB, Padmanabhan S, Haessler J, Bartz TM, Waldenberger M, Lichtner P, Arendt M, Krieger JE, Kahonen M, Risch L, Mansur AJ, Peters A, Smith BH, Lind L, Scott SA, Lu Y, Bottinger EB, Hernesniemi J, Lindgren CM, Wong JA, Huang J, Eskola M, Morris AP, Ford I, Reiner AP, Delgado G, Chen LY, Chen YI, Sandhu RK, Li M, Boerwinkle E, Eisele L, Lannfelt L, Rost N et al (2017) Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. Nat Genet 49:946–952. https://doi.org/10.1038/ng.3843CrossRefPubMedPubMedCentral

41.

Chua W, Purmah Y, Cardoso VR, Gkoutos GV, Tull SP, Neculau G, Thomas MR, Kotecha D, Lip GYH, Kirchhof P, Fabritz L (2019) Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation. Eur Heart J 40:1268–1276. https://doi.org/10.1093/eurheartj/ehy815CrossRefPubMedPubMedCentral

42.

Chung CC, Lin YK, Chen YC, Kao YH, Yeh YH, Trang NN, Chen YJ (2023) Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis. Cardiovasc Diabetol 22:27. https://doi.org/10.1186/s12933-023-01756-0CrossRefPubMedPubMedCentral

43.

Chung MK, Eckhardt LL, Chen LY, Ahmed HM, Gopinathannair R, Joglar JA, Noseworthy PA, Pack QR, Sanders P, Trulock KM, American Heart Association E, Arrhythmias C, Exercise CR, Secondary Prevention Committee of the Council on Clinical C, Council on Arteriosclerosis T, Vascular B, Council on C, Stroke N, Council on L, Cardiometabolic H (2020) Lifestyle and risk factor modification for reduction of atrial fibrillation: a scientific statement from the American heart association. Circulation 141:e750–e772. https://doi.org/10.1161/CIR.0000000000000748CrossRef

44.

Clausen AG, Vad OB, Andersen JH, Olesen MS (2021) Loss–of-function variants in the SYNPO2L gene are associated with atrial fibrillation. Front Cardiovasc Med 8:650667. https://doi.org/10.3389/fcvm.2021.650667CrossRefPubMedPubMedCentral

45.

Clauss S, Wakili R, Hildebrand B, Kaab S, Hoster E, Klier I, Martens E, Hanley A, Hanssen H, Halle M, Nickel T (2016) MicroRNAs as biomarkers for acute atrial remodeling in marathon runners (the miRathon study—a sub-study of the munich marathon study). PLoS ONE 11:e0148599. https://doi.org/10.1371/journal.pone.0148599CrossRefPubMedPubMedCentral

46.

Clementy N, Garcia B, Andre C, Bisson A, Benhenda N, Pierre B, Bernard A, Fauchier L, Piver E, Babuty D (2018) Galectin-3 level predicts response to ablation and outcomes in patients with persistent atrial fibrillation and systolic heart failure. PLoS ONE 13:e0201517. https://doi.org/10.1371/journal.pone.0201517CrossRefPubMedPubMedCentral

47.

Clementy N, Piver E, Bisson A, Andre C, Bernard A, Pierre B, Fauchier L, Babuty D (2018) Galectin-3 in atrial fibrillation: mechanisms and therapeutic implications. Int J Mol Sci. https://doi.org/10.3390/ijms19040976CrossRefPubMedPubMedCentral

48.

Conen D, Ke Wang M, Popova E, Chan MTV, Landoni G, Cata JP, Reimer C, McLean SR, Srinathan SK, Reyes JCT, Grande AM, Tallada AG, Sessler DI, Fleischmann E, Kabon B, Voltolini L, Cruz P, Maziak DE, Gutierrez-Soriano L, McIntyre WF, Tandon V, Martinez-Tellez E, Guerra-Londono JJ, DuMerton D, Wong RHL, McGuire AL, Kidane B, Roux DP, Shargall Y, Wells JR, Ofori SN, Vincent J, Xu L, Li Z, Eikelboom JW, Jolly SS, Healey JS, Devereaux PJ, Investigators C-A (2023) Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial. Lancet. https://doi.org/10.1016/S0140-6736(23)01689-6CrossRefPubMed

49.

Conway DS, Buggins P, Hughes E, Lip GY (2004) Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 43:2075–2082. https://doi.org/10.1016/j.jacc.2003.11.062CrossRefPubMed

50.

Corradi D (2014) Atrial fibrillation from the pathologist’s perspective. Cardiovasc Pathol 23:71–84. https://doi.org/10.1016/j.carpath.2013.12.001CrossRefPubMed

51.

Corradi D, Callegari S, Maestri R, Ferrara D, Mangieri D, Alinovi R, Mozzoni P, Pinelli S, Goldoni M, Privitera YA, Bartoli V, Astorri E, Macchi E, Vaglio A, Benussi S, Alfieri O (2012) Differential structural remodeling of the left-atrial posterior wall in patients affected by mitral regurgitation with or without persistent atrial fibrillation: a morphological and molecular study. J Cardiovasc Electrophys 23:271–279. https://doi.org/10.1111/j.1540-8167.2011.02187.xCrossRef

52.

Cunha PS, Laranjo S, Heijman J, Oliveira MM (2022) The atrium in atrial fibrillation—a clinical review on how to manage atrial fibrotic substrates. Front Cardiovasc Med 9:879984. https://doi.org/10.3389/fcvm.2022.879984CrossRefPubMedPubMedCentral

53.

Dawson K, Wakili R, Ordog B, Clauss S, Chen Y, Iwasaki Y, Voigt N, Qi XY, Sinner MF, Dobrev D, Kaab S, Nattel S (2013) MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.112.001207CrossRefPubMed

54.

den Uijl DW, Delgado V, Bertini M, Tops LF, Trines SA, van de Veire NR, Zeppenfeld K, Schalij MJ, Bax JJ (2011) Impact of left atrial fibrosis and left atrial size on the outcome of catheter ablation for atrial fibrillation. Heart 97:1847–1851. https://doi.org/10.1136/hrt.2010.215335CrossRef

55.

den Uijl DW, Gawrysiak M, Tops LF, Trines SA, Zeppenfeld K, Schalij MJ, Bax JJ, Delgado V (2011) Prognostic value of total atrial conduction time estimated with tissue Doppler imaging to predict the recurrence of atrial fibrillation after radiofrequency catheter ablation. Europace 13:1533–1540. https://doi.org/10.1093/europace/eur186CrossRef

56.

Disertori M, Mase M, Marini M, Mazzola S, Cristoforetti A, Del Greco M, Kottkamp H, Arbustini E, Ravelli F (2014) Electroanatomic mapping and late gadolinium enhancement MRI in a genetic model of arrhythmogenic atrial cardiomyopathy. J Cardiovasc Electrophys 25:964–970. https://doi.org/10.1111/jce.12440CrossRef

57.

Dobrev D, Heijman J, Hiram R, Li N, Nattel S (2023) Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology. Nat Rev Cardiol 20:145–167. https://doi.org/10.1038/s41569-022-00759-wCrossRefPubMed

58.

Donal E, Lip GY, Galderisi M, Goette A, Shah D, Marwan M, Lederlin M, Mondillo S, Edvardsen T, Sitges M, Grapsa J, Garbi M, Senior R, Gimelli A, Potpara TS, Van Gelder IC, Gorenek B, Mabo P, Lancellotti P, Kuck KH, Popescu BA, Hindricks G, Habib G, Cardim NM, Cosyns B, Delgado V, Haugaa KH, Muraru D, Nieman K, Boriani G, Cohen A (2016) EACVI/EHRA expert consensus document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation. Eur Heart J Cardiovasc Imag 17:355–383. https://doi.org/10.1093/ehjci/jev354CrossRef

59.

Donate Puertas R, Millat G, Ernens I, Gache V, Chauveau S, Morel E, Christin E, Couturier N, Devaux Y, Chevalier P (2018) Atrial structural remodeling gene variants in patients with atrial fibrillation. Biom Res Int 2018:4862480. https://doi.org/10.1155/2018/4862480CrossRef

60.

Du J, Xie J, Zhang Z, Tsujikawa H, Fusco D, Silverman D, Liang B, Yue L (2010) TRPM7-mediated Ca2+ signals confer fibrogenesis in human atrial fibrillation. Circ Res 106:992–1003. https://doi.org/10.1161/CIRCRESAHA.109.206771CrossRefPubMedPubMedCentral

61.

Duprez DA, Heckbert SR, Alonso A, Gross MD, Ix JH, Kizer JR, Tracy RP, Kronmal R, Jacobs DR Jr (2018) Collagen biomarkers and incidence of new onset of atrial fibrillation in subjects with no overt cardiovascular disease at baseline: the multi-ethnic study of atherosclerosis. Circ Arrhythm Electrophys 11:e006557. https://doi.org/10.1161/CIRCEP.118.006557CrossRef

62.

Elson EL, Qian H, Fee JA, Wakatsuki T (2019) A model for positive feedback control of the transformation of fibroblasts to myofibroblasts. Prog Biophys Mol Biol 144:30–40. https://doi.org/10.1016/j.pbiomolbio.2018.08.004CrossRefPubMed

63.

Engstrom A, Wintzell V, Melbye M, Hviid A, Eliasson B, Gudbjornsdottir S, Hveem K, Jonasson C, Svanstrom H, Pasternak B, Ueda P (2023) Sodium–Glucose cotransporter 2 inhibitor treatment and risk of atrial fibrillation: scandinavian cohort study. Diabet Care 46:351–360. https://doi.org/10.2337/dc22-0714CrossRef

64.

Eranti A, Aro AL, Kerola T, Anttonen O, Rissanen HA, Tikkanen JT, Junttila MJ, Kentta TV, Knekt P, Huikuri HV (2014) Prevalence and prognostic significance of abnormal P terminal force in lead V1 of the ECG in the general population. Circ Arrhythm Electroph 7:1116–1121. https://doi.org/10.1161/CIRCEP.114.001557CrossRef

65.

Ezeani M, Hagemeyer CE, Lal S, Niego B (2022) Molecular imaging of atrial myopathy: towards early AF detection and non-invasive disease management. Trend Cardiovasc Med 32:20–31. https://doi.org/10.1016/j.tcm.2020.12.002CrossRef

66.

Farinha JM, Gupta D, Lip GYH (2022) Frequent premature atrial contractions as a signalling marker of atrial cardiomyopathy, incident atrial fibrillation and stroke. Cardiovasc Res. https://doi.org/10.1093/cvr/cvac054CrossRefPubMedCentral

67.

Fauchier L, Clementy N, Babuty D (2013) Statin therapy and atrial fibrillation: systematic review and updated meta–analysis of published randomized controlled trials. Curr Opin Cardiol 28:7–18. https://doi.org/10.1097/HCO.0b013e32835b0956CrossRefPubMed

68.

Fender AC, Kleeschulte S, Stolte S, Leineweber K, Kamler M, Bode J, Li N, Dobrev D (2020) Thrombin receptor PAR4 drives canonical NLRP3 inflammasome signaling in the heart. Basic Res Cardiol 115:10. https://doi.org/10.1007/s00395-019-0771-9CrossRefPubMedPubMedCentral

69.

Fender AC, Wakili R, Dobrev D (2019) Straight to the heart: pleiotropic antiarrhythmic actions of oral anticoagulants. Pharmacol Res 145:104257. https://doi.org/10.1016/j.phrs.2019.104257CrossRefPubMedPubMedCentral

70.

Filipovic K, Bellmann B, Sultan A, J LU, Plenge T, Steven D, (2021) Hydrochlorothiazide therapy: impact on early recurrence of atrial fibrillation after catheter ablation? Minerva Cardiol Angiol 69:102–108. https://doi.org/10.23736/S2724-5683.20.05170-1CrossRefPubMed

71.

Fogari R, Mugellini A, Zoppi A, Preti P, Destro M, Lazzari P, Derosa G (2012) Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. J Cardiovasc Pharmacol Ther 17:34–43. https://doi.org/10.1177/1074248410395018CrossRefPubMed

72.

Franco D, Chinchilla A, Daimi H, Dominguez JN, Aranega A (2011) Modulation of conductive elements by Pitx2 and their impact on atrial arrhythmogenesis. Cardiovasc Res 91:223–231. https://doi.org/10.1093/cvr/cvr078CrossRefPubMed

73.

Freestone B, Chong AY, Nuttall S, Lip GY (2008) Impaired flow mediated dilatation as evidence of endothelial dysfunction in chronic atrial fibrillation: relationship to plasma von Willebrand factor and soluble E-selectin levels. Thromb Res 122:85–90. https://doi.org/10.1016/j.thromres.2007.09.008CrossRefPubMed

74.

Fullerton JL, Thomas JM, Gonzalez-Trueba L, Trivett C, van Kralingen JC, Allan SM, Quinn TJ, Work LM (2022) Systematic review: association between circulating microRNA expression and stroke. J Cereb Blood Flow Metab 42:935–951. https://doi.org/10.1177/0271678X221085090CrossRefPubMedPubMedCentral

75.

Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, Ferrucci L, Gilroy DW, Fasano A, Miller GW, Miller AH, Mantovani A, Weyand CM, Barzilai N, Goronzy JJ, Rando TA, Effros RB, Lucia A, Kleinstreuer N, Slavich GM (2019) Chronic inflammation in the etiology of disease across the life span. Nat Med 25:1822–1832. https://doi.org/10.1038/s41591-019-0675-0CrossRefPubMedPubMedCentral

76.

Gal P, Klaassen ES, Bergmann KR, Saghari M, Burggraaf J, Kemme MJB, Sylvest C, Sorensen U, Bentzen BH, Grunnet M, Diness JG, Edvardsson N (2020) First clinical study with AP30663-a K(Ca) 2 channel inhibitor in development for conversion of atrial fibrillation. Clin Transl Sci 13:1336–1344. https://doi.org/10.1111/cts.12835CrossRefPubMedPubMedCentral

77.

Gang UJ, Nalliah CJ, Lim TW, Thiagalingam A, Kovoor P, Ross DL, Thomas SP (2015) Atrial ectopy predicts late recurrence of atrial fibrillation after pulmonary vein isolation. Circ Arrhythm Electrophysiol 8:569–574. https://doi.org/10.1161/CIRCEP.114.002052CrossRefPubMed

78.

Gao RF, Li X, Xiang HY, Yang H, Lv CY, Sun XL, Chen HZ, Gao Y, Yang JS, Luo W, Yang YQ, Tang YH (2021) The covalent NLRP3-inflammasome inhibitor oridonin relieves myocardial infarction induced myocardial fibrosis and cardiac remodeling in mice. Int Immunopharmacol 90:107133. https://doi.org/10.1016/j.intimp.2020.107133CrossRefPubMed

79.

Gharibeh L, Yamak A, Whitcomb J, Lu A, Joyal M, Komati H, Liang W, Fiset C, Nemer M (2021) GATA6 is a regulator of sinus node development and heart rhythm. Proc Natl Acad Sci USA. https://doi.org/10.1073/pnas.2007322118CrossRefPubMed

80.

Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, Vaid H, O’Donnell M, Laupacis A, Cote R, Sharma M, Blakely JA, Shuaib A, Hachinski V, Coutts SB, Sahlas DJ, Teal P, Yip S, Spence JD, Buck B, Verreault S, Casaubon LK, Penn A, Selchen D, Jin A, Howse D, Mehdiratta M, Boyle K, Aviv R, Kapral MK, Mamdani M, Investigators E, Coordinators, (2014) Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 370:2467–2477. https://doi.org/10.1056/NEJMoa1311376CrossRefPubMed

81.

Goette A, Hammwohner M, Bukowska A, Scalera F, Martens-Lobenhoffer J, Dobrev D, Ravens U, Weinert S, Medunjanin S, Lendeckel U, Bode-Boger SM (2012) The impact of rapid atrial pacing on ADMA and endothelial NOS. Int J Cardiol 154:141–146. https://doi.org/10.1016/j.ijcard.2010.09.004CrossRefPubMed

82.

Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA, Chugh SS, Corradi D, D’Avila A, Dobrev D, Fenelon G, Gonzalez M, Hatem SN, Helm R, Hindricks G, Ho SY, Hoit B, Jalife J, Kim YH, Lip GY, Ma CS, Marcus GM, Murray K, Nogami A, Sanders P, Uribe W, Van Wagoner DR, Nattel S, Document R (2016) EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace 18:1455–1490. https://doi.org/10.1093/europace/euw161CrossRefPubMedPubMedCentral

83.

Goetze JP, Bruneau BG, Ramos HR, Ogawa T, de Bold MK, de Bold AJ (2020) Cardiac natriuretic peptides. Nat Rev Cardiol 17:698–717. https://doi.org/10.1038/s41569-020-0381-0CrossRefPubMed

84.

Goldberger JJ, Arora R, Green D, Greenland P, Lee DC, Lloyd-Jones DM, Markl M, Ng J, Shah SJ (2015) Evaluating the atrial myopathy underlying atrial fibrillation: identifying the arrhythmogenic and thrombogenic substrate. Circulation 132:278–291. https://doi.org/10.1161/CIRCULATIONAHA.115.016795CrossRefPubMedPubMedCentral

85.

Goldman ME, Pearce LA, Hart RG, Zabalgoitia M, Asinger RW, Safford R, Halperin JL (1999) Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. reduced flow velocity in the left atrial appendage (the stroke prevention in atrial fibrillation [SPAF-III] study). J Am Soc Echocardiogr 12:1080–1087. https://doi.org/10.1016/s0894-7317(99)70105-7CrossRefPubMed

86.

Gottlieb LA, Coronel R, Dekker LRC (2023) Reduction in atrial and pulmonary vein stretch as a therapeutic target for prevention of atrial fibrillation. Heart Rhythm 20:291–298. https://doi.org/10.1016/j.hrthm.2022.10.009CrossRefPubMed

87.

Greulich S, Maxhera B, Vandenplas G, de Wiza DH, Smiris K, Mueller H, Heinrichs J, Blumensatt M, Cuvelier C, Akhyari P, Ruige JB, Ouwens DM, Eckel J (2012) Secretory products from epicardial adipose tissue of patients with type 2 diabetes mellitus induce cardiomyocyte dysfunction. Circulation 126:2324–2334. https://doi.org/10.1161/CIRCULATIONAHA.111.039586CrossRefPubMed

88.

Groh WJ (2012) Arrhythmias in the muscular dystrophies. Heart Rhythm 9:1890–1895. https://doi.org/10.1016/j.hrthm.2012.06.038CrossRefPubMed

89.

Guidera SA, Steinberg JS (1993) The signal-averaged P wave duration: a rapid and noninvasive marker of risk of atrial fibrillation. J Am Coll Cardiol 21:1645–1651. https://doi.org/10.1016/0735-1097(93)90381-aCrossRefPubMed

90.

Guo XJ, Qiu XB, Wang J, Guo YH, Yang CX, Li L, Gao RF, Ke ZP, Di RM, Sun YM, Xu YJ, Yang YQ (2021) PRRX1 Loss-of-function mutations underlying familial atrial fibrillation. J Am Heart Assoc 10:e023517. https://doi.org/10.1161/JAHA.121.023517CrossRefPubMedPubMedCentral

91.

Guo Y, Lip GY, Apostolakis S (2012) Inflammation in atrial fibrillation. J Am Coll Cardiol 60:2263–2270. https://doi.org/10.1016/j.jacc.2012.04.063CrossRefPubMed

92.

Gutierrez A, Chung MK (2016) Genomics of atrial fibrillation. Curr Cardiol Rep 18:55. https://doi.org/10.1007/s11886-016-0735-8CrossRefPubMedPubMedCentral

93.

Haemers P, Hamdi H, Guedj K, Suffee N, Farahmand P, Popovic N, Claus P, LePrince P, Nicoletti A, Jalife J, Wolke C, Lendeckel U, Jais P, Willems R, Hatem SN (2017) Atrial fibrillation is associated with the fibrotic remodelling of adipose tissue in the subepicardium of human and sheep atria. Eur Heart J 38:53–61. https://doi.org/10.1093/eurheartj/ehv625CrossRefPubMed

94.

Harada M, Luo X, Qi XY, Tadevosyan A, Maguy A, Ordog B, Ledoux J, Kato T, Naud P, Voigt N, Shi Y, Kamiya K, Murohara T, Kodama I, Tardif JC, Schotten U, Van Wagoner DR, Dobrev D, Nattel S (2012) Transient receptor potential canonical-3 channel-dependent fibroblast regulation in atrial fibrillation. Circulation 126:2051–2064. https://doi.org/10.1161/CIRCULATIONAHA.112.121830CrossRefPubMedPubMedCentral

95.

Harada M, Melka J, Sobue Y, Nattel S (2017) Metabolic considerations in atrial fibrillation—mechanistic insights and therapeutic opportunities. Circ J 81:1749–1757. https://doi.org/10.1253/circj.CJ-17-1058CrossRefPubMed

96.

He S, Wang Y, Yao Y, Cao Z, Yin J, Zi L, Chen H, Fu Y, Wang X, Zhao Q (2021) Inhibition of KCa3. 1 channels suppresses atrial fibrillation via the attenuation of macrophage pro-inflammatory polarization in a canine model with prolonged rapid atrial pacing. Front Cardiovasc Med. https://doi.org/10.3389/fcvm.2021.656631CrossRefPubMedPubMedCentral

97.

Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH, Investigators A (2012) Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 366:120–129. https://doi.org/10.1056/NEJMoa1105575CrossRefPubMed

98.

Healey JS, Gladstone DJ, Swaminathan B, Eckstein J, Mundl H, Epstein AE, Haeusler KG, Mikulik R, Kasner SE, Toni D, Arauz A, Ntaios G, Hankey GJ, Perera K, Pagola J, Shuaib A, Lutsep H, Yang X, Uchiyama S, Endres M, Coutts SB, Karlinski M, Czlonkowska A, Molina CA, Santo G, Berkowitz SD, Hart RG, Connolly SJ (2019) Recurrent stroke with rivaroxaban compared with aspirin according to predictors of atrial fibrillation: secondary analysis of the NAVIGATE ESUS randomized clinical trial. JAMA Neurol 76:764–773. https://doi.org/10.1001/jamaneurol.2019.0617CrossRefPubMedPubMedCentral

99.

Heijman J, Muna AP, Veleva T, Molina CE, Sutanto H, Tekook M, Wang Q, Abu-Taha IH, Gorka M, Kunzel S, El-Armouche A, Reichenspurner H, Kamler M, Nikolaev V, Ravens U, Li N, Nattel S, Wehrens XHT, Dobrev D (2020) Atrial myocyte NLRP3/CaMKII nexus forms a substrate for postoperative atrial fibrillation. Circ Res 127:1036–1055. https://doi.org/10.1161/CIRCRESAHA.120.316710CrossRefPubMedPubMedCentral

100.

Heijman J, Zhou X, Morotti S, Molina CE, Abu-Taha IH, Tekook M, Jespersen T, Zhang Y, Dobrev S, Milting H, Gummert J, Karck M, Kamler M, El-Armouche A, Saljic A, Grandi E, Nattel S, Dobrev D (2023) Enhanced Ca(2+)-dependent SK-channel gating and membrane trafficking in human atrial fibrillation. Circ Res 132:e116–e133. https://doi.org/10.1161/CIRCRESAHA.122.321858CrossRefPubMed

101.

Hermans MC, Pinto YM, Merkies IS, de Die-Smulders CE, Crijns HJ, Faber CG (2010) Hereditary muscular dystrophies and the heart. Neuromuscul Disord 20:479–492. https://doi.org/10.1016/j.nmd.2010.04.008CrossRefPubMed

102.

Herrera MD, Mingorance C, Rodriguez-Rodriguez R, Alvarez de Sotomayor M (2010) Endothelial dysfunction and aging: an update. Ageing Res Rev 9:142–152. https://doi.org/10.1016/j.arr.2009.07.002CrossRefPubMed

103.

Hijazi Z, Oldgren J, Siegbahn A, Wallentin L (2017) Application of biomarkers for risk stratification in patients with atrial fibrillation. Clin Chem 63:152–164. https://doi.org/10.1373/clinchem.2016.255182CrossRefPubMed

104.

Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL, Group ESCSD (2021) 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European society of cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC. Eur Heart J 42:373–498. https://doi.org/10.1093/eurheartj/ehaa612CrossRef

105.

Hiram R, Xiong F, Naud P, Xiao J, Sirois M, Tanguay JF, Tardif JC, Nattel S (2021) The inflammation-resolution promoting molecule resolvin-D1 prevents atrial proarrhythmic remodelling in experimental right heart disease. Cardiovasc Res 117:1776–1789. https://doi.org/10.1093/cvr/cvaa186CrossRefPubMed

106.

Hu HJ, Zhang C, Tang ZH, Qu SL, Jiang ZS (2019) Regulating the Warburg effect on metabolic stress and myocardial fibrosis remodeling and atrial intracardiac waveform activity induced by atrial fibrillation. Biochem Biophys Res Commun 516:653–660. https://doi.org/10.1016/j.bbrc.2019.06.055CrossRefPubMed

107.

Hu YF, Chen YJ, Lin YJ, Chen SA (2015) Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol 12:230–243. https://doi.org/10.1038/nrcardio.2015.2CrossRefPubMed

108.

Hua R, MacLeod SL, Polina I, Moghtadaei M, Jansen HJ, Bogachev O, O’Blenes SB, Sapp JL, Legare JF, Rose RA (2015) Effects of wild-type and mutant forms of atrial natriuretic peptide on atrial electrophysiology and arrhythmogenesis. Circ Arrhythm Electroph 8:1240–1254. https://doi.org/10.1161/CIRCEP.115.002896CrossRef

109.

Hulsmans M, Schloss MJ, Lee IH, Bapat A, Iwamoto Y, Vinegoni C, Paccalet A, Yamazoe M, Grune J, Pabel S, Momin N, Seung H, Kumowski N, Pulous FE, Keller D, Bening C, Green U, Lennerz JK, Mitchell RN, Lewis A, Casadei B, Iborra-Egea O, Bayes-Genis A, Sossalla S, Ong CS, Pierson RN, Aster JC, Rohde D, Wojtkiewicz GR, Weissleder R, Swirski FK, Tellides G, Tolis G Jr, Melnitchouk S, Milan DJ, Ellinor PT, Naxerova K, Nahrendorf M (2023) Recruited macrophages elicit atrial fibrillation. Science 381:231–239. https://doi.org/10.1126/science.abq3061CrossRefPubMedPubMedCentral

110.

Huynh K (2023) Ruxolitinib is a CaMKII inhibitor that can be repurposed to prevent arrhythmias. Nat Rev Cardiol 20:580. https://doi.org/10.1038/s41569-023-00910-1CrossRefPubMed

111.

Inciardi RM, Bonelli A, Biering-Sorensen T, Cameli M, Pagnesi M, Lombardi CM, Solomon SD, Metra M (2022) Left atrial disease and left atrial reverse remodelling across different stages of heart failure development and progression: a new target for prevention and treatment. Eur J Heart Fail 24:959–975. https://doi.org/10.1002/ejhf.2562CrossRefPubMed

112.

Inoue YY, Alissa A, Khurram IM, Fukumoto K, Habibi M, Venkatesh BA, Zimmerman SL, Nazarian S, Berger RD, Calkins H, Lima JA, Ashikaga H (2015) Quantitative tissue-tracking cardiac magnetic resonance (CMR) of left atrial deformation and the risk of stroke in patients with atrial fibrillation. J Am Heart Assoc. https://doi.org/10.1161/JAHA.115.001844CrossRefPubMedPubMedCentral

113.

Jalife J, Kaur K (2015) Atrial remodeling, fibrosis, and atrial fibrillation. Trend Cardiovasc Med 25:475–484. https://doi.org/10.1016/j.tcm.2014.12.015CrossRef

114.

Jameson HS, Hanley A, Hill MC, Xiao L, Ye J, Bapat A, Ronzier E, Hall AW, Hucker WJ, Clauss S, Barazza M, Silber E, Mina JA, Tucker NR, Mills RW, Dong JT, Milan DJ, Ellinor PT (2023) Loss of the atrial fibrillation-related gene, Zfhx3, results in atrial dilation and arrhythmias. Circ Res 133:313–329. https://doi.org/10.1161/CIRCRESAHA.123.323029CrossRefPubMed

115.

January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW (2019) 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American Heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation 140:e125–e151. https://doi.org/10.1161/CIR.0000000000000665CrossRefPubMed

116.

Jhaveri S, Aziz PF, Saarel E (2018) Expanding the electrical phenotype of NKX2-5 mutations: ventricular tachycardia, atrial fibrillation, and complete heart block within one family. Heart Rhythm Case Rep 4:530–533. https://doi.org/10.1016/j.hrcr.2018.08.001CrossRef

117.

Jiang H, Wang W, Wang C, Xie X, Hou Y (2017) Association of pre-ablation level of potential blood markers with atrial fibrillation recurrence after catheter ablation: a meta-analysis. Europace 19:392–400. https://doi.org/10.1093/europace/euw088CrossRefPubMed

118.

Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, Deswal A, Eckhardt LL, Goldberger ZD, Gopinathannair R, Gorenek B, Hess PL, Hlatky M, Hogan G, Ibeh C, Indik JH, Kido K, Kusumoto F, Link MS, Linta KT, Marcus GM, McCarthy PM, Patel N, Patton KK, Perez MV, Piccini JP, Russo AM, Sanders P, Streur MM, Thomas KL, Times S, Tisdale JE, Valente AM, Van Wagoner DR (2024) 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation 149:e1–e156. https://doi.org/10.1161/CIR.0000000000001193CrossRefPubMed

119.

Johansen MC, Doria de Vasconcellos H, Nazarian S, Lima JAC, Gottesman RF (2021) The investigation of left atrial structure and stroke etiology: the I-LASER study. J Am Heart Assoc 10:e018766. https://doi.org/10.1161/JAHA.120.018766CrossRefPubMedPubMedCentral

120.

Johnson RD, Camelliti P (2018) Role of non-myocyte gap junctions and connexin hemichannels in cardiovascular health and disease: novel therapeutic targets? Int J Mol Sci. https://doi.org/10.3390/ijms19030866CrossRefPubMedPubMedCentral

121.

Jung M, Kim JS, Song JH, Kim JM, Park KY, Lee WS, Kim SW, Lip GY, Shin SY (2020) Usefulness of P wave duration in embolic stroke of undetermined source. J Clin Med. https://doi.org/10.3390/jcm9041134CrossRefPubMedPubMedCentral

122.

Kallergis EM, Goudis CA, Vardas PE (2014) Atrial fibrillation: a progressive atrial myopathy or a distinct disease? Int J Cardiol 171:126–133. https://doi.org/10.1016/j.ijcard.2013.12.009CrossRefPubMed

123.

Kallergis EM, Manios EG, Kanoupakis EM, Mavrakis HE, Kolyvaki SG, Lyrarakis GM, Chlouverakis GI, Vardas PE (2008) The role of the post-cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation. Heart 94:200–204. https://doi.org/10.1136/hrt.2006.108688CrossRefPubMed

124.

Kalstad AA, Myhre PL, Laake K, Opstad TB, Tveit A, Solheim S, Arnesen H, Seljeflot I (2021) Biomarkers of ageing and cardiac remodeling are associated with atrial fibrillation. Scand Cardiovasc J 55:213–219. https://doi.org/10.1080/14017431.2021.1889653CrossRefPubMed

125.

Kalsto SM, Siland JE, Rienstra M, Christophersen IE (2019) Atrial fibrillation genetics update: toward clinical implementation. Front Cardiovasc Med 6:127. https://doi.org/10.3389/fcvm.2019.00127CrossRefPubMedPubMedCentral

126.

Kamel H, Hunter M, Moon YP, Yaghi S, Cheung K, Di Tullio MR, Okin PM, Sacco RL, Soliman EZ, Elkind MS (2015) Electrocardiographic left atrial abnormality and risk of stroke: northern manhattan study. Stroke 46:3208–3212. https://doi.org/10.1161/STROKEAHA.115.009989CrossRefPubMedPubMedCentral

127.

Kamel H, Longstreth WT Jr, Tirschwell DL, Kronmal RA, Broderick JP, Palesch YY, Meinzer C, Dillon C, Ewing I, Spilker JA, Di Tullio MR, Hod EA, Soliman EZ, Chaturvedi S, Moy CS, Janis S, Elkind MS (2019) The AtRial cardiopathy and antithrombotic drugs in prevention after cryptogenic stroke randomized trial: rationale and methods. Int J Stroke 14:207–214. https://doi.org/10.1177/1747493018799981CrossRefPubMed

128.

Kaplan RC, McGinn AP, Pollak MN, Kuller LH, Strickler HD, Rohan TE, Cappola AR, Xue X, Psaty BM (2007) Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. J Clin Endocrinol Metab 92:1319–1325. https://doi.org/10.1210/jc.2006-1631CrossRefPubMed

129.

Kato T, Sekiguchi A, Sagara K, Tanabe H, Takamura M, Kaneko S, Aizawa T, Fu LT, Yamashita T (2017) Endothelial-mesenchymal transition in human atrial fibrillation. J Cardiol 69:706–711. https://doi.org/10.1016/j.jjcc.2016.10.014CrossRefPubMed

130.

Ke ZP, Zhang GF, Guo YH, Sun YM, Wang J, Li N, Qiu XB, Xu YJ, Yang YQ (2022) A novel PRRX1 loss-of-function variation contributing to familial atrial fibrillation and congenital patent ductus arteriosus. Genet Mol Biol 45:e20210378. https://doi.org/10.1590/1678-4685-GMB-2021-0378CrossRefPubMedPubMedCentral

131.

Kemp Gudmundsdottir K, Fredriksson T, Svennberg E, Al-Khalili F, Friberg L, Frykman V, Hijazi Z, Rosenqvist M, Engdahl J (2020) Stepwise mass screening for atrial fibrillation using N-terminal B-type natriuretic peptide: the STROKESTOP II study. Europace 22:24–32. https://doi.org/10.1093/europace/euz255CrossRefPubMed

132.

Khan MS, Memon MM, Murad MH, Vaduganathan M, Greene SJ, Hall M, Triposkiadis F, Lam CSP, Shah AM, Butler J, Shah SJ (2020) Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Eur J Heart Fail 22:472–485. https://doi.org/10.1002/ejhf.1643CrossRefPubMed

133.

Khatib R, Joseph P, Briel M, Yusuf S, Healey J (2013) Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials. Int J Cardiol 165:17–24. https://doi.org/10.1016/j.ijcard.2012.02.009CrossRefPubMed

134.

Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, Natarajan P, Lander ES, Lubitz SA, Ellinor PT, Kathiresan S (2018) Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet 50:1219–1224. https://doi.org/10.1038/s41588-018-0183-zCrossRefPubMedPubMedCentral

135.

Khurshid S, Friedman S, Reeder C, Di Achille P, Diamant N, Singh P, Harrington LX, Wang X, Al-Alusi MA, Sarma G, Foulkes AS, Ellinor PT, Anderson CD, Ho JE, Philippakis AA, Batra P, Lubitz SA (2022) ECG-based deep learning and clinical risk factors to predict atrial fibrillation. Circulation 145:122–133. https://doi.org/10.1161/CIRCULATIONAHA.121.057480CrossRefPubMed

136.

Kiliszek M, Maciak K, Maciejak A, Krzyzanowski K, Wierzbowski R, Gora M, Burzynska B, Segiet A, Skrobowski A (2020) Serum microRNA in patients undergoing atrial fibrillation ablation. Sci Rep 10:4424. https://doi.org/10.1038/s41598-020-61322-6CrossRefPubMedPubMedCentral

137.

Kim H, Kang MG, Park HW, Park JR, Hwang JY, Kim K (2021) Anderson-Fabry disease presenting with atrial fibrillation as earlier sign in a young patient: a case report. World J Clin Cases 9:4823–4828. https://doi.org/10.12998/wjcc.v9.i18.4823CrossRefPubMedPubMedCentral

138.

Kim MY, Coyle C, Tomlinson DR, Sikkel MB, Sohaib A, Luther V, Leong KM, Malcolme-Lawes L, Low B, Sandler B, Lim E, Todd M, Fudge M, Wright IJ, Koa-Wing M, Ng FS, Qureshi NA, Whinnett ZI, Peters NS, Newcomb D, Wood C, Dhillon G, Hunter RJ, Lim PB, Linton NWF, Kanagaratnam P (2022) Ectopy-triggering ganglionated plexuses ablation to prevent atrial fibrillation: GANGLIA-AF study. Heart Rhythm 19:516–524. https://doi.org/10.1016/j.hrthm.2021.12.010CrossRefPubMedPubMedCentral

139.

Kim SK, Pak HN, Park JH, Ko KJ, Lee JS, Choi JI, Choi DH, Kim YH (2009) Clinical and serological predictors for the recurrence of atrial fibrillation after electrical cardioversion. Europace 11:1632–1638. https://doi.org/10.1093/europace/eup321CrossRefPubMed

140.

King JB, Azadani PN, Suksaranjit P, Bress AP, Witt DM, Han FT, Chelu MG, Silver MA, Biskupiak J, Wilson BD, Morris AK, Kholmovski EG, Marrouche N (2017) Left atrial fibrosis and risk of cerebrovascular and cardiovascular events in patients with atrial fibrillation. J Am Coll Cardiol 70:1311–1321. https://doi.org/10.1016/j.jacc.2017.07.758CrossRefPubMed

141.

Kirchhof P, Kahr PC, Kaese S, Piccini I, Vokshi I, Scheld HH, Rotering H, Fortmueller L, Laakmann S, Verheule S, Schotten U, Fabritz L, Brown NA (2011) PITX2c is expressed in the adult left atrium, and reducing Pitx2c expression promotes atrial fibrillation inducibility and complex changes in gene expression. Circ Cardiovasc Genet 4:123–133. https://doi.org/10.1161/CIRCGENETICS.110.958058CrossRefPubMed

142.

Kishima H, Mine T, Takahashi S, Ashida K, Ishihara M, Masuyama T (2017) The impact of transforming growth factor-beta(1) level on outcome after catheter ablation in patients with atrial fibrillation. J Cardiovasc Electroph 28:402–409. https://doi.org/10.1111/jce.13169CrossRef

143.

Koizumi T, Watanabe M, Yokota T, Tsuda M, Handa H, Koya J, Nishino K, Tatsuta D, Natsui H, Kadosaka T, Koya T, Nakao M, Hagiwara H, Kamada R, Temma T, Tanaka S, Anzai T (2023) Empagliflozin suppresses mitochondrial reactive oxygen species generation and mitigates the inducibility of atrial fibrillation in diabetic rats. Front Cardiovasc Med 10:1005408. https://doi.org/10.3389/fcvm.2023.1005408CrossRefPubMedPubMedCentral

144.

Komal S, Yin JJ, Wang SH, Huang CZ, Tao HL, Dong JZ, Han SN, Zhang LR (2019) MicroRNAs: emerging biomarkers for atrial fibrillation. J Cardiol 74:475–482. https://doi.org/10.1016/j.jjcc.2019.05.018CrossRefPubMed

145.

Korantzopoulos P, Kolettis TM, Galaris D, Goudevenos JA (2007) The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol 115:135–143. https://doi.org/10.1016/j.ijcard.2006.04.026CrossRefPubMed

146.

Kottkamp H (2012) Fibrotic atrial cardiomyopathy: a specific disease/syndrome supplying substrates for atrial fibrillation, atrial tachycardia, sinus node disease, AV node disease, and thromboembolic complications. J Cardiovasc Electroph 23:797–799. https://doi.org/10.1111/j.1540-8167.2012.02341.xCrossRef

147.

Krishnan A, Chilton E, Raman J, Saxena P, McFarlane C, Trollope AF, Kinobe R, Chilton L (2021) Are interactions between epicardial adipose tissue, cardiac fibroblasts and cardiac myocytes instrumental in atrial fibrosis and atrial fibrillation? Cells. https://doi.org/10.3390/cells10092501CrossRefPubMedPubMedCentral

148.

Krishnappa D, Dykoski R, Can I, Mbai M, Anand IS, Florea V, Chandrashekar YS, Li JM, Tholakanahalli VN (2019) Atrial fibrillation in the elderly: the role of sub-clinical isolated cardiac amyloidosis. Sci Rep 9:16584. https://doi.org/10.1038/s41598-019-53119-zCrossRefPubMedPubMedCentral

149.

Kubota T, Kawasaki M, Takasugi N, Takeyama U, Ishihara Y, Okubo M, Yamaki T, Ojio S, Aoyama T, Arai M, Nishigaki K, Takemura G, Fujiwara H, Minatoguchi S (2009) Evaluation of left atrial degeneration for the prediction of atrial fibrillation: usefulness of integrated backscatter transesophageal echocardiography. JACC Cardiovasc Imag 2:1039–1047. https://doi.org/10.1016/j.jcmg.2009.03.021CrossRef

150.

Kugler S, Onodi Z, Ruppert M, Sayour AA, Olah A, Benke K, Ferdinandy P, Merkely B, Radovits T, Varga ZV (2022) Inflammasome activation in end-stage heart failure-associated atrial fibrillation. ESC Heart Fail 9:2747–2752. https://doi.org/10.1002/ehf2.13972CrossRefPubMedPubMedCentral

151.

Kulkarni K, Singh JP, Parks KA, Katritsis DG, Stavrakis S, Armoundas AA (2021) Low-level tragus stimulation modulates atrial alternans and fibrillation burden in patients with paroxysmal atrial fibrillation. J Am Heart Assoc 10:e020865. https://doi.org/10.1161/JAHA.120.020865CrossRefPubMedPubMedCentral

152.

Lage R, Cebro-Marquez M, Vilar-Sanchez ME, Gonzalez-Melchor L, Garcia-Seara J, Martinez-Sande JL, Fernandez-Lopez XA, Aragon-Herrera A, Martinez-Monzonis MA, Gonzalez-Juanatey JR, Rodriguez-Manero M, Moscoso I (2023) Circulating miR-451a expression may predict recurrence in atrial fibrillation patients after catheter pulmonary vein ablation. Cells. https://doi.org/10.3390/cells12040638CrossRefPubMedPubMedCentral

153.

Lai YJ, Tsai FC, Chang GJ, Chang SH, Huang CC, Chen WJ, Yeh YH (2022) miR-181b targets semaphorin 3A to mediate TGF-beta-induced endothelial-mesenchymal transition related to atrial fibrillation. J Clin Invest. https://doi.org/10.1172/JCI142548CrossRefPubMedPubMedCentral

154.

Larsen BS, Olsen FJ, Andersen DM, Madsen CV, Mogelvang R, Jensen GB, Schnohr P, Aplin M, Host NB, Christensen H, Sajadieh A, Biering-Sorensen T (2022) Left atrial volumes and function, and long-term incidence of ischemic stroke in the general population. J Am Heart Assoc 11:e027031. https://doi.org/10.1161/JAHA.122.027031CrossRefPubMedPubMedCentral

155.

Larsen BT, Maleszewski JJ, Edwards WD, Cooper LT Jr, Sobonya RE, Thompson VE, Duckett SG, Peebles CR, Simpson IA, Tazelaar HD (2013) Atrial giant cell myocarditis: a distinctive clinicopathologic entity. Circulation 127:39–47. https://doi.org/10.1161/CIRCULATIONAHA.112.128900CrossRefPubMed

156.

Lavall D, Selzer C, Schuster P, Lenski M, Adam O, Schafers HJ, Bohm M, Laufs U (2014) The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation. J Biol Chem 289:6656–6668. https://doi.org/10.1074/jbc.M113.519256CrossRefPubMedPubMedCentral

157.

Lee DK, Shim J, Choi JI, Kim YH, Oh YW, Hwang SH (2019) Left atrial fibrosis assessed with cardiac mri in patients with paroxysmal and those with persistent atrial fibrillation. Radiology 292:575–582. https://doi.org/10.1148/radiol.2019182629CrossRefPubMed

158.

Lee JM, Seo J, Uhm JS, Kim YJ, Lee HJ, Kim JY, Sung JH, Pak HN, Lee MH, Joung B (2015) Why is left atrial appendage morphology related to strokes? an analysis of the flow velocity and orifice size of the left atrial appendage. J Cardiovasc Electroph 26:922–927. https://doi.org/10.1111/jce.12710CrossRef

159.

Lee K, Lee SK, Lee J, Jeon BK, Kim TH, Yu HT, Lee JM, Park JK, Baek YS, Kim DH, Shim J, Joung B, Lee MH, Pak HN, Park J (2023) Protocol of BEYOND trial: clinical BEnefit of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in rhYthm cONtrol of atrial fibrillation in patients with diabetes mellitus. PLoS ONE 18:e0280359. https://doi.org/10.1371/journal.pone.0280359CrossRefPubMedPubMedCentral

160.

Lee KW, Everett THt, Rahmutula D, Guerra JM, Wilson E, Ding C, Olgin JE (2006) Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.106.624320CrossRefPubMedPubMedCentral

161.

Lee SR, Choi EK, Jung JH, Han KD, Oh S, Lip GYH (2021) Lower risk of stroke after alcohol abstinence in patients with incident atrial fibrillation: a nationwide population-based cohort study. Eur Heart J 42:4759–4768. https://doi.org/10.1093/eurheartj/ehab315CrossRefPubMedPubMedCentral

162.

Lewis GA, Dodd S, Clayton D, Bedson E, Eccleson H, Schelbert EB, Naish JH, Jimenez BD, Williams SG, Cunnington C, Ahmed FZ, Cooper A, Rajavarma V, Russell S, McDonagh T, Williamson PR, Miller CA (2021) Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial. Nat Med 27:1477–1482. https://doi.org/10.1038/s41591-021-01452-0CrossRefPubMed

163.

Li J, Yang Y, Ng CY, Zhang Z, Liu T, Li G (2016) Association of plasma transforming growth factor-beta1 levels and the risk of atrial fibrillation: a meta-analysis. PLoS ONE 11:e0155275. https://doi.org/10.1371/journal.pone.0155275CrossRefPubMedPubMedCentral

164.

Li L, Hua C, Liu X, Wang Y, Zhao L, Zhang Y, Wang L, Su P, Yang MF, Xie B (2023) SGLT2i alleviates epicardial adipose tissue inflammation by modulating ketone body-glyceraldehyde-3-phosphate dehydrogenase malonylation pathway. J Cardiovasc Med 24:232–243. https://doi.org/10.2459/JCM.0000000000001453CrossRef

165.

Li N, Brundel B (2020) Inflammasomes and proteostasis novel molecular mechanisms associated with atrial fibrillation. Circ Res 127:73–90. https://doi.org/10.1161/CIRCRESAHA.119.316364CrossRefPubMedPubMedCentral

166.

Li Y, Li W, Yang B, Han W, Dong D, Xue J, Li B, Yang S, Sheng L (2007) Effects of cilazapril on atrial electrical, structural and functional remodeling in atrial fibrillation dogs. J Electrocardiol 40(100):e101-106. https://doi.org/10.1016/j.jelectrocard.2006.04.001CrossRef

167.

Lin C, Bao Y, Xie Y, Wei Y, Luo Q, Ling T, Jin Q, Pan W, Xie Y, Wu L, Zhang N (2022) Prognostic implications of left atrial spontaneous echo contrast with catheter ablation of nonvalvular atrial fibrillation patients with left atrial dilation. J Cardiovasc Dev Dis. https://doi.org/10.3390/jcdd9090306CrossRefPubMedPubMedCentral

168.

Lin YK, Chen YA, Lee TI, Chen YC, Chen SA, Chen YJ (2018) Aging modulates the substrate and triggers remodeling in atrial fibrillation. Circ J 82:1237–1244. https://doi.org/10.1253/circj.CJ-17-0242CrossRefPubMed

169.

Liu H, Wang K, Lin Y, Liang X, Zhao S, Li M, Chen M (2020) Role of sST2 in predicting recurrence of atrial fibrillation after radiofrequency catheter ablation. Pacing Clin Electroph 43:1235–1241. https://doi.org/10.1111/pace.14029CrossRef

170.

Liu Y, Bai F, Liu N, Ouyang F, Liu Q (2019) The Warburg effect: a new insight into atrial fibrillation. Clin Chim Acta 499:4–12. https://doi.org/10.1016/j.cca.2019.08.029CrossRefPubMed

171.

Liu Y, Shi Q, Ma Y, Liu Q (2018) The role of immune cells in atrial fibrillation. J Mol Cell Cardiol 123:198–208. https://doi.org/10.1016/j.yjmcc.2018.09.007CrossRefPubMed

172.

Liu Y, Zhou H, Tao Y, Xu Z, Lai H (2022) Relationship between serum miR-106 and MYL4 levels and the prevalence, risk stratification, and prognosis of atrial fibrillation. J Immunol Res 2022:1069866. https://doi.org/10.1155/2022/1069866CrossRefPubMedPubMedCentral

173.

Low SK, Takahashi A, Ebana Y, Ozaki K, Christophersen IE, Ellinor PT, Consortium AF, Ogishima S, Yamamoto M, Satoh M, Sasaki M, Yamaji T, Iwasaki M, Tsugane S, Tanaka K, Naito M, Wakai K, Tanaka H, Furukawa T, Kubo M, Ito K, Kamatani Y, Tanaka T (2017) Identification of six new genetic loci associated with atrial fibrillation in the Japanese population. Nat Genet 49:953–958. https://doi.org/10.1038/ng.3842CrossRef

174.

Lu Y, Hou S, Huang D, Luo X, Zhang J, Chen J, Xu W (2015) Expression profile analysis of circulating microRNAs and their effects on ion channels in Chinese atrial fibrillation patients. Int J Clin Exp Med 8:845–853PubMedPubMedCentral

175.

Lui DTW, Tang EHM, Wu T, Au ICH, Lee CH, Woo YC, Tan KCB, Wong CKH (2023) Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong. Cardiovasc Diabetol 22:40. https://doi.org/10.1186/s12933-023-01772-0CrossRefPubMedPubMedCentral

176.

Ma X, Yuan H, Luan HX, Shi YL, Zeng XL, Wang Y (2018) Elevated soluble ST2 concentration may involve in the progression of atrial fibrillation. Clin Chim Acta 480:138–142. https://doi.org/10.1016/j.cca.2018.02.005CrossRefPubMed

177.

Mahajan R, Lau DH, Brooks AG, Shipp NJ, Manavis J, Wood JP, Finnie JW, Samuel CS, Royce SG, Twomey DJ, Thanigaimani S, Kalman JM, Sanders P (2015) Electrophysiological, electroanatomical, and structural remodeling of the atria as consequences of sustained obesity. J Am Coll Cardiol 66:1–11. https://doi.org/10.1016/j.jacc.2015.04.058CrossRefPubMed

178.

Maharani N, Ting YK, Cheng J, Hasegawa A, Kurata Y, Li P, Nakayama Y, Ninomiya H, Ikeda N, Morikawa K, Yamamoto K, Makita N, Yamashita T, Shirayoshi Y, Hisatome I (2015) Molecular mechanisms underlying urate-induced enhancement of Kv1.5 channel expression in HL-1 atrial myocytes. Circ J 79:2659–2668. https://doi.org/10.1253/circj.CJ-15-0416CrossRefPubMed

179.

Manninger M, Zweiker D, van Hunnik A, Alogna A, Prassl AJ, Schipke J, Zeemering S, Zirngast B, Schonleitner P, Schwarzl M, Herbst V, Thon-Gutschi E, Huber S, Rohrer U, Ebner J, Brussee H, Pieske BM, Heinzel FR, Verheule S, Antoons G, Lueger A, Muhlfeld C, Plank G, Schotten U, Post H, Scherr D (2018) Arterial hypertension drives arrhythmia progression via specific structural remodeling in a porcine model of atrial fibrillation. Heart Rhythm 15:1328–1336. https://doi.org/10.1016/j.hrthm.2018.05.016CrossRefPubMed

180.

Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F, Kholmovski E, Burgon N, Hu N, Mont L, Deneke T, Duytschaever M, Neumann T, Mansour M, Mahnkopf C, Herweg B, Daoud E, Wissner E, Bansmann P, Brachmann J (2014) Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA 311:498–506. https://doi.org/10.1001/jama.2014.3CrossRefPubMed

181.

Martin DT, Bersohn MM, Waldo AL, Wathen MS, Choucair WK, Lip GY, Ip J, Holcomb R, Akar JG, Halperin JL, Investigators I (2015) Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. Eur Heart J 36:1660–1668. https://doi.org/10.1093/eurheartj/ehv115CrossRefPubMed

182.

Masuda M, Fujita M, Iida O, Okamoto S, Ishihara T, Nanto K, Kanda T, Tsujimura T, Matsuda Y, Okuno S, Ohashi T, Tsuji A, Mano T (2018) Left atrial low-voltage areas predict atrial fibrillation recurrence after catheter ablation in patients with paroxysmal atrial fibrillation. Int J Cardiol 257:97–101. https://doi.org/10.1016/j.ijcard.2017.12.089CrossRefPubMed

183.

McManus DD, Lin H, Tanriverdi K, Quercio M, Yin X, Larson MG, Ellinor PT, Levy D, Freedman JE, Benjamin EJ (2014) Relations between circulating microRNAs and atrial fibrillation: data from the framingham offspring study. Heart Rhythm 11:663–669. https://doi.org/10.1016/j.hrthm.2014.01.018CrossRefPubMedPubMedCentral

184.

McManus DD, Tanriverdi K, Lin H, Esa N, Kinno M, Mandapati D, Tam S, Okike ON, Ellinor PT, Keaney JF Jr, Donahue JK, Benjamin EJ, Freedman JE (2015) Plasma microRNAs are associated with atrial fibrillation and change after catheter ablation (the miRhythm study). Heart Rhythm 12:3–10. https://doi.org/10.1016/j.hrthm.2014.09.050CrossRefPubMed

185.

Mehta D, Willner JM, Akhrass PR (2015) Atrial fibrillation in cardiac sarcoidosis. J Atr Fibr 8:1288. https://doi.org/10.4022/jafib.1288CrossRef

186.

Mehta PK, Griendling KK (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292:C82-97. https://doi.org/10.1152/ajpcell.00287.2006CrossRefPubMed

187.

Middeldorp ME, Pathak RK, Meredith M, Mehta AB, Elliott AD, Mahajan R, Twomey D, Gallagher C, Hendriks JML, Linz D, McEvoy RD, Abhayaratna WP, Kalman JM, Lau DH, Sanders P (2018) PREVEntion and regReSsive effect of weight-loss and risk factor modification on atrial fibrillation: the REVERSE-AF study. Europace 20:1929–1935. https://doi.org/10.1093/europace/euy117CrossRefPubMed

188.

Milliez P, Deangelis N, Rucker-Martin C, Leenhardt A, Vicaut E, Robidel E, Beaufils P, Delcayre C, Hatem SN (2005) Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J 26:2193–2199. https://doi.org/10.1093/eurheartj/ehi478CrossRefPubMed

189.

Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45:1243–1248. https://doi.org/10.1016/j.jacc.2005.01.015CrossRefPubMed

190.

Miragoli M, Gaudesius G, Rohr S (2006) Electrotonic modulation of cardiac impulse conduction by myofibroblasts. Circ Res 98:801–810. https://doi.org/10.1161/01.RES.0000214537.44195.a3CrossRefPubMed

191.

Molina CE, Abu-Taha IH, Wang Q, Rosello-Diez E, Kamler M, Nattel S, Ravens U, Wehrens XHT, Hove-Madsen L, Heijman J, Dobrev D (2018) Profibrotic, electrical, and calcium-handling remodeling of the atria in heart failure patients with and without atrial fibrillation. Front Physiol 9:1383. https://doi.org/10.3389/fphys.2018.01383CrossRefPubMedPubMedCentral

192.

Moreira LM, Takawale A, Hulsurkar M, Menassa DA, Antanaviciute A, Lahiri SK, Mehta N, Evans N, Psarros C, Robinson P, Sparrow AJ, Gillis MA, Ashley N, Naud P, Barallobre-Barreiro J, Theofilatos K, Lee A, Norris M, Clarke MV, Russell PK, Casadei B, Bhattacharya S, Zajac JD, Davey RA, Sirois M, Mead A, Simmons A, Mayr M, Sayeed R, Krasopoulos G, Redwood C, Channon KM, Tardif JC, Wehrens XHT, Nattel S, Reilly S (2020) Paracrine signalling by cardiac calcitonin controls atrial fibrogenesis and arrhythmia. Nature 587:460–465. https://doi.org/10.1038/s41586-020-2890-8CrossRefPubMed

193.

Muller P, Makimoto H, Dietrich JW, Fochler F, Nentwich K, Krug J, Duncker D, Blockhaus C, Kelm M, Furnkranz A, Deneke T, Halbfass P (2018) Association of left atrial low-voltage area and thromboembolic risk in patients with atrial fibrillation. Europace 20:f359–f365. https://doi.org/10.1093/europace/eux172CrossRefPubMed

194.

Mustroph J, Lebek S, Maier LS, Neef S (2019) Mechanisms of cardiac ethanol toxicity and novel treatment options. Pharmacol Ther 197:1–10. https://doi.org/10.1016/j.pharmthera.2018.12.006CrossRefPubMed

195.

Nattel S (2017) Molecular and cellular mechanisms of atrial fibrosis in atrial fibrillation. JACC Clin Electroph 3:425–435. https://doi.org/10.1016/j.jacep.2017.03.002CrossRef

196.

Nattel S, Dobrev D (2016) Electrophysiological and molecular mechanisms of paroxysmal atrial fibrillation. Nat Rev Cardiol 13:575–590. https://doi.org/10.1038/nrcardio.2016.118CrossRefPubMed

197.

Nattel S, Heijman J, Zhou L, Dobrev D (2020) Molecular basis of atrial fibrillation pathophysiology and therapy: a translational perspective. Circ Res 127:51–72. https://doi.org/10.1161/CIRCRESAHA.120.316363CrossRefPubMedPubMedCentral

198.

Nattel SH, J., Voigt, N., Wehrens, X., Dobrev, D. (2018) The molecular pathophysiology of atrial fibrillation. In: Jalife J (ed) Cardiac electrophysiology: from cell to bedside, 7th edn. Elsevier, Philadelphia, pp 396–408CrossRef

199.

Nedios S, Tang M, Roser M, Solowjowa N, Gerds-Li JH, Fleck E, Kriatselis C (2011) Characteristic changes of volume and three-dimensional structure of the left atrium in different forms of atrial fibrillation: predictive value after ablative treatment. J Interv Card Electroph 32:87–94. https://doi.org/10.1007/s10840-011-9591-zCrossRef

200.

Nortamo S, Ukkola O, Lepojarvi S, Kentta T, Kiviniemi A, Junttila J, Huikuri H, Perkiomaki J (2017) Association of sST2 and hs-CRP levels with new-onset atrial fibrillation in coronary artery disease. Int J Cardiol 248:173–178. https://doi.org/10.1016/j.ijcard.2017.07.022CrossRefPubMed

201.

Noseworthy PA, Attia ZI, Behnken EM, Giblon RE, Bews KA, Liu S, Gosse TA, Linn ZD, Deng Y, Yin J, Gersh BJ, Graff-Radford J, Rabinstein AA, Siontis KC, Friedman PA, Yao X (2022) Artificial intelligence-guided screening for atrial fibrillation using electrocardiogram during sinus rhythm: a prospective non-randomised interventional trial. Lancet 400:1206–1212. https://doi.org/10.1016/S0140-6736(22)01637-3CrossRefPubMed

202.

Obokata M, Reddy YNV, Yang JH, Wiley BM, Borlaug BA (2018) Left Atrial Contracture or failure to dilate. Circ Heart Fail 11:e005163. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005163CrossRefPubMedPubMedCentral

203.

Ohlrogge AH, Frost L, Schnabel RB (2022) Harmful impact of tobacco smoking and alcohol consumption on the atrial myocardium. Cells. https://doi.org/10.3390/cells11162576CrossRefPubMedPubMedCentral

204.

Olesen MS, Yuan L, Liang B, Holst AG, Nielsen N, Nielsen JB, Hedley PL, Christiansen M, Olesen SP, Haunso S, Schmitt N, Jespersen T, Svendsen JH (2012) High prevalence of long QT syndrome-associated SCN5A variants in patients with early-onset lone atrial fibrillation. Circ Cardiovasc Genet 5:450–459. https://doi.org/10.1161/CIRCGENETICS.111.962597CrossRefPubMed

205.

Olsen FJ, Pedersen S, Jensen JS, Biering-Sorensen T (2016) Global longitudinal strain predicts incident atrial fibrillation and stroke occurrence after acute myocardial infarction. Medicine 95:e5338. https://doi.org/10.1097/MD.0000000000005338CrossRefPubMedPubMedCentral

206.

Olshansky B, Heller EN, Mitchell LB, Chandler M, Slater W, Green M, Brodsky M, Barrell P, Greene HL (2005) Are transthoracic echocardiographic parameters associated with atrial fibrillation recurrence or stroke? results from the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. J Am Coll Cardiol 45:2026–2033. https://doi.org/10.1016/j.jacc.2005.03.020CrossRefPubMed

207.

Ovchinnikov AG, Potekhina A, Belyavskiy E, Gvozdeva A, Ageev F (2022) Left atrial dysfunction as the major driver of heart failure with preserved ejection fraction syndrome. J Clin Ultrasound 50:1073–1083. https://doi.org/10.1002/jcu.23318CrossRefPubMed

208.

Panagal M, Biruntha M, Vidhyavathi RM, Sivagurunathan P, Senthilkumar SR, Sekar D (2019) Dissecting the role of miR-21 in different types of stroke. Gene 681:69–72. https://doi.org/10.1016/j.gene.2018.09.048CrossRefPubMed

209.

Pascual-Figal DA, Januzzi JL (2015) The biology of ST2: the International ST2 consensus panel. Am J Cardiol 115:3B-7B. https://doi.org/10.1016/j.amjcard.2015.01.034CrossRefPubMed

210.

Patel AJ, Lazdunski M, Honore E (2001) Lipid and mechano-gated 2P domain K(+) channels. Curr Opin Cell Biol 13:422–428. https://doi.org/10.1016/s0955-0674(00)00231-3CrossRefPubMed

211.

Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, Alasady M, Hanley L, Antic NA, McEvoy RD, Kalman JM, Abhayaratna WP, Sanders P (2014) Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol 64:2222–2231. https://doi.org/10.1016/j.jacc.2014.09.028CrossRefPubMed

212.

Patti G, Lucerna M, Pecen L, Siller-Matula JM, Cavallari I, Kirchhof P, De Caterina R (2017) Thromboembolic risk, bleeding outcomes and effect of different antithrombotic strategies in very elderly patients with atrial fibrillation: a sub-analysis from the prefer in af (prevention of thromboembolic events-european registry in atrial fibrillation). J Am Heart Assoc. https://doi.org/10.1161/JAHA.117.005657CrossRefPubMedPubMedCentral

213.

Paul A, Pai PG, Ariyannur PS, Joy RA (2021) Diagnostic accuracy of MicroRNA 208b level with respect to different types of atrial fibrillation. Indian Heart J 73:506–510. https://doi.org/10.1016/j.ihj.2021.06.018CrossRefPubMedPubMedCentral

214.

Peigh G, Shah SJ, Patel RB (2021) Left atrial myopathy in atrial fibrillation and heart failure: clinical implications, mechanisms, and therapeutic targets. Curr Heart Fail Rep 18:85–98. https://doi.org/10.1007/s11897-021-00510-5CrossRefPubMedPubMedCentral

215.

Peng W, Li M, Li H, Tang K, Zhuang J, Zhang J, Xiao J, Jiang H, Li D, Yu Y, Sham PC, Nattel S, Xu Y (2017) Dysfunction of myosin light-chain 4 (MYL4) leads to heritable atrial cardiomyopathy with electrical, contractile, and structural components: evidence from genetically-engineered rats. J Am Heart Assoc. https://doi.org/10.1161/JAHA.117.007030CrossRefPubMedPubMedCentral

216.

Perregaux DG, McNiff P, Laliberte R, Hawryluk N, Peurano H, Stam E, Eggler J, Griffiths R, Dombroski MA, Gabel CA (2001) Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors. J Pharmacol Exp Ther 299:187–197PubMed

217.

Perrot A, Tomasov P, Villard E, Faludi R, Melacini P, Lossie J, Lohmann N, Richard P, De Bortoli M, Angelini A, Varga-Szemes A, Sperling SR, Simor T, Veselka J, Ozcelik C, Charron P (2016) Mutations in NEBL encoding the cardiac Z-disk protein nebulette are associated with various cardiomyopathies. Arch Med Sci 12:263–278. https://doi.org/10.5114/aoms.2016.59250CrossRefPubMedPubMedCentral

218.

Pezhouman A, Cao H, Fishbein MC, Belardinelli L, Weiss JN, Karagueuzian HS (2018) Atrial fibrillation initiated by early afterdepolarization-mediated triggered activity during acute oxidative stress: efficacy of late sodium current blockade. J Heart Health. https://doi.org/10.1696/2379-769X.146CrossRefPubMedPubMedCentral

219.

Pirault J, Back M (2018) Lipoxin and resolvin receptors transducing the resolution of inflammation in cardiovascular disease. Front Pharmacol 9:1273. https://doi.org/10.3389/fphar.2018.01273CrossRefPubMedPubMedCentral

220.

Polovina MM, Lip GY, Potpara TS (2015) Endothelial (dys)function in lone atrial fibrillation. Curr Pharm Des 21:622–645. https://doi.org/10.2174/1381612820666140825143028CrossRefPubMed

221.

Postma AV, van de Meerakker JB, Mathijssen IB, Barnett P, Christoffels VM, Ilgun A, Lam J, Wilde AA, Lekanne Deprez RH, Moorman AF (2008) A gain-of-function TBX5 mutation is associated with atypical Holt-Oram syndrome and paroxysmal atrial fibrillation. Circ Res 102:1433–1442. https://doi.org/10.1161/CIRCRESAHA.107.168294CrossRefPubMed

222.

Pradhan K, Niehues P, Neupane B, Maleck C, Sharif-Yakan A, Emrani M, Zink MD, Napp A, Marx N, Gramlich M (2023) MicroRNA-21 mediated cross-talk between cardiomyocytes and fibroblasts in patients with atrial fibrillation. Front Cardiovasc Med 10:1056134. https://doi.org/10.3389/fcvm.2023.1056134CrossRefPubMedPubMedCentral

223.

Pranata R, Yonas E, Vania R (2019) Prolonged P-wave duration in sinus rhythm pre-ablation is associated with atrial fibrillation recurrence after pulmonary vein isolation-a systematic review and meta-analysis. Ann Noninvasive Electrocardiol 24:e12653. https://doi.org/10.1111/anec.12653CrossRefPubMedPubMedCentral

224.

Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, White R, Furberg CD, Rautaharju PM (1997) Incidence of and risk factors for atrial fibrillation in older adults. Circulation 96:2455–2461. https://doi.org/10.1161/01.cir.96.7.2455CrossRefPubMed

225.

Purohit A, Rokita AG, Guan X, Chen B, Koval OM, Voigt N, Neef S, Sowa T, Gao Z, Luczak ED, Stefansdottir H, Behunin AC, Li N, El-Accaoui RN, Yang B, Swaminathan PD, Weiss RM, Wehrens XH, Song LS, Dobrev D, Maier LS, Anderson ME (2013) Oxidized Ca(2+)/calmodulin-dependent protein kinase II triggers atrial fibrillation. Circulation 128:1748–1757. https://doi.org/10.1161/CIRCULATIONAHA.113.003313CrossRefPubMed

226.

Py A, Schaaf M, Duhamel S, Si-Mohamed S, Daher J, Altman M, de Breyne B, Mechtouff L, Placide J, Chauveau S, Chevalier P, Nighoghossian N, Bergerot C, Thibault H (2020) Atrial premature activity detected after an ischaemic stroke unveils atrial myopathy. Arch Cardiovasc Dis 113:227–236. https://doi.org/10.1016/j.acvd.2019.12.002CrossRefPubMed

227.

Qin X, Zhang Y, Zheng Q (2022) Metabolic inflexibility as a pathogenic basis for atrial fibrillation. Int J Mol Sci. https://doi.org/10.3390/ijms23158291CrossRefPubMedPubMedCentral

228.

Quail M, Grunseich K, Baldassarre LA, Mojibian H, Marieb MA, Cornfeld D, Soufer A, Sinusas AJ, Peters DC (2019) Prognostic and functional implications of left atrial late gadolinium enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson 21:2. https://doi.org/10.1186/s12968-018-0514-3CrossRefPubMedPubMedCentral

229.

Ravassa S, Ballesteros G, Lopez B, Ramos P, Bragard J, Gonzalez A, Moreno MU, Querejeta R, Vives E, Garcia-Bolao I, Diez J (2019) Combination of circulating type I collagen-related biomarkers is associated with atrial fibrillation. J Am Coll Cardiol 73:1398–1410. https://doi.org/10.1016/j.jacc.2018.12.074CrossRefPubMed

230.

Reddy YNV, Borlaug BA, Gersh BJ (2022) Management of atrial fibrillation across the spectrum of heart failure with preserved and reduced ejection fraction. Circulation 146:339–357. https://doi.org/10.1161/CIRCULATIONAHA.122.057444CrossRefPubMed

231.

Reddy YNV, El Sabbagh A, Packer D, Nishimura RA (2018) Evaluation of shortness of breath after atrial fibrillation ablation—is there a stiff left atrium? Heart Rhythm 15:930–935. https://doi.org/10.1016/j.hrthm.2018.01.029CrossRefPubMed

232.

Reddy YNV, Obokata M, Verbrugge FH, Lin G, Borlaug BA (2020) Atrial dysfunction in patients with heart failure with preserved ejection fraction and atrial fibrillation. J Am Coll Cardiol 76:1051–1064. https://doi.org/10.1016/j.jacc.2020.07.009CrossRefPubMedPubMedCentral

233.

Reyes Gaido OE, Pavlaki N, Granger JM, Mesubi OO, Liu B, Lin BL, Long A, Walker D, Mayourian J, Schole KL, Terrillion CE, Nkashama LJ, Hulsurkar MM, Dorn LE, Ferrero KM, Huganir RL, Muller FU, Wehrens XHT, Liu JO, Luczak ED, Bezzerides VJ, Anderson ME (2023) An improved reporter identifies ruxolitinib as a potent and cardioprotective CaMKII inhibitor. Sci Transl Med. https://doi.org/10.1126/scitranslmed.abq7839CrossRefPubMed

234.

Richter B, Derntl M, Marx M, Lercher P, Gossinger HD (2007) Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation. Am Heart J 153:113–119. https://doi.org/10.1016/j.ahj.2006.09.006CrossRefPubMed

235.

Rienstra M, Siland JE, Ellinor PT (2021) Role of genetics in atrial fibrillation management. Europace. https://doi.org/10.1093/europace/euaa366CrossRefPubMedPubMedCentral

236.

Rienstra M, Yin X, Larson MG, Fontes JD, Magnani JW, McManus DD, McCabe EL, Coglianese EE, Amponsah M, Ho JE, Januzzi JL Jr, Wollert KC, Fradley MG, Vasan RS, Ellinor PT, Wang TJ, Benjamin EJ (2014) Relation between soluble ST2, growth differentiation factor-15, and high-sensitivity troponin I and incident atrial fibrillation. Am Heart J 167(109–115):e102. https://doi.org/10.1016/j.ahj.2013.10.003CrossRef

237.

Rivner H, Mitrani RD, Goldberger JJ (2020) Atrial myopathy underlying atrial fibrillation. Arrhythm Electroph Rev 9:61–70. https://doi.org/10.15420/aer.2020.13CrossRef

238.

Rochette L, Lorin J, Zeller M, Guilland JC, Lorgis L, Cottin Y, Vergely C (2013) Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets? Pharmacol Ther 140:239–257. https://doi.org/10.1016/j.pharmthera.2013.07.004CrossRefPubMed

239.

Rocken C, Peters B, Juenemann G, Saeger W, Klein HU, Huth C, Roessner A, Goette A (2002) Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation 106:2091–2097. https://doi.org/10.1161/01.cir.0000034511.06350.dfCrossRefPubMed

240.

Roldan V, Marin F, Muina B, Torregrosa JM, Hernandez-Romero D, Valdes M, Vicente V, Lip GY (2011) Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol 57:2496–2504. https://doi.org/10.1016/j.jacc.2010.12.033CrossRefPubMed

241.

Rolf S, Kircher S, Arya A, Eitel C, Sommer P, Richter S, Gaspar T, Bollmann A, Altmann D, Piedra C, Hindricks G, Piorkowski C (2014) Tailored atrial substrate modification based on low-voltage areas in catheter ablation of atrial fibrillation. Circ Arrhythm Electroph 7:825–833. https://doi.org/10.1161/CIRCEP.113.001251CrossRef

242.

Rosa MI, Grande AJ, Lima LD, Dondossola ER, Uggioni MLR, Hernandez AV, Tse G, Liu T, Pontes-Neto OM, Biondi-Zoccai G, Neto MG, Duraes AR, Sa M, Resende ES, Roever L (2021) Association between epicardial adipose tissue and stroke. Front Cardiovasc Med 8:658445. https://doi.org/10.3389/fcvm.2021.658445CrossRefPubMedPubMedCentral

243.

Roselli C, Rienstra M, Ellinor PT (2020) Genetics of atrial fibrillation in 2020: GWAS, genome sequencing, polygenic risk, and beyond. Circ Res 127:21–33. https://doi.org/10.1161/CIRCRESAHA.120.316575CrossRefPubMedPubMedCentral

244.

Rosenberg MA, Maziarz M, Tan AY, Glazer NL, Zieman SJ, Kizer JR, Ix JH, Djousse L, Siscovick DS, Heckbert SR, Mukamal KJ (2014) Circulating fibrosis biomarkers and risk of atrial fibrillation: the cardiovascular health study (CHS). Am Heart J 167(723–728):e722. https://doi.org/10.1016/j.ahj.2014.01.010CrossRef

245.

Saber H, Himali JJ, Beiser AS, Shoamanesh A, Pikula A, Roubenoff R, Romero JR, Kase CS, Vasan RS, Seshadri S (2017) Serum insulin-like growth factor 1 and the risk of ischemic stroke: the framingham study. Stroke 48:1760–1765. https://doi.org/10.1161/STROKEAHA.116.016563CrossRefPubMedPubMedCentral

246.

Sajeev JK, Kalman JM, Dewey H, Cooke JC, Teh AW (2020) The atrium and embolic stroke: myopathy not atrial fibrillation as the requisite determinant? JACC Clin Electroph 6:251–261. https://doi.org/10.1016/j.jacep.2019.12.013CrossRef

247.

Sajeev JK, Koshy AN, Dewey H, Kalman JM, Rajakariar K, Tan MC, Street M, Roberts L, Cooke JC, Wong M, Frost T, Teh AW (2019) Association between excessive premature atrial complexes and cryptogenic stroke: results of a case-control study. BMJ Open 9:e029164. https://doi.org/10.1136/bmjopen-2019-029164CrossRefPubMedPubMedCentral

248.

Sakabe M, Fujiki A, Nishida K, Sugao M, Nagasawa H, Tsuneda T, Mizumaki K, Inoue H (2004) Enalapril prevents perpetuation of atrial fibrillation by suppressing atrial fibrosis and over-expression of connexin43 in a canine model of atrial pacing-induced left ventricular dysfunction. J Cardiovasc Pharmacol 43:851–859. https://doi.org/10.1097/00005344-200406000-00015CrossRefPubMed

249.

Salah A, Zhou S, Liu Q, Yan H (2013) P wave indices to predict atrial fibrillation recurrences post pulmonary vein isolation. Arq Bras Cardiol 101:519–527. https://doi.org/10.5935/abc.20130214CrossRefPubMedPubMedCentral

250.

Saljic A, Grandi E, Dobrev D (2022) TGF-beta1-induced endothelial-mesenchymal transition: a potential contributor to fibrotic remodeling in atrial fibrillation? J Clin Invest. https://doi.org/10.1172/JCI161070CrossRefPubMedPubMedCentral

251.

Sardana M, Lessard D, Tsao CW, Parikh NI, Barton BA, Nah G, Thomas RC, Cheng S, Schiller NB, Aragam JR, Mitchell GF, Vaze A, Benjamin EJ, Vasan RS, McManus DD (2018) Association of left atrial function index with atrial fibrillation and cardiovascular disease: the framingham offspring study. J Am Heart Assoc. https://doi.org/10.1161/JAHA.117.008435CrossRefPubMedPubMedCentral

252.

Sardana M, Ogunsua AA, Spring M, Shaikh A, Asamoah O, Stokken G, Browning C, Ennis C, Donahue JK, Rosenthal LS, Floyd KC, Aurigemma GP, Parikh NI, McManus DD (2016) Association of left atrial function index with late atrial fibrillation recurrence after catheter ablation. J Cardiovasc Electroph 27:1411–1419. https://doi.org/10.1111/jce.13086CrossRef

253.

Sato S, Suzuki J, Hirose M, Yamada M, Zenimaru Y, Nakaya T, Ichikawa M, Imagawa M, Takahashi S, Ikuyama S, Konoshita T, Kraemer FB, Ishizuka T (2019) Cardiac overexpression of perilipin 2 induces atrial steatosis, connexin 43 remodeling, and atrial fibrillation in aged mice. Am J Physiol Endocrinol Metab 317:E1193–E1204. https://doi.org/10.1152/ajpendo.00227.2019CrossRefPubMedPubMedCentral

254.

Schmidt C, Wiedmann F, Voigt N, Zhou XB, Heijman J, Lang S, Albert V, Kallenberger S, Ruhparwar A, Szabo G, Kallenbach K, Karck M, Borggrefe M, Biliczki P, Ehrlich JR, Baczko I, Lugenbiel P, Schweizer PA, Donner BC, Katus HA, Dobrev D, Thomas D (2015) Upregulation of K(2P)3.1 K+ current causes action potential shortening in patients with chronic atrial fibrillation. Circulation 132:82–92. https://doi.org/10.1161/CIRCULATIONAHA.114.012657CrossRefPubMed

255.

Scott L Jr, Fender AC, Saljic A, Li L, Chen X, Wang X, Linz D, Lang J, Hohl M, Twomey D, Pham TT, Diaz-Lankenau R, Chelu MG, Kamler M, Entman ML, Taffet GE, Sanders P, Dobrev D, Li N (2021) NLRP3 inflammasome is a key driver of obesity-induced atrial arrhythmias. Cardiovasc Res 117:1746–1759. https://doi.org/10.1093/cvr/cvab024CrossRefPubMed

256.

Scott L Jr, Li N, Dobrev D (2019) Role of inflammatory signaling in atrial fibrillation. Int J Cardiol 287:195–200. https://doi.org/10.1016/j.ijcard.2018.10.020CrossRefPubMed

257.

Scridon A, Girerd N, Rugeri L, Nonin-Babary E, Chevalier P (2013) Progressive endothelial damage revealed by multilevel von Willebrand factor plasma concentrations in atrial fibrillation patients. Europace 15:1562–1566. https://doi.org/10.1093/europace/eut121CrossRefPubMed

258.

Seljeflot I, S RU, Enger S, Bratseth V, Arnesen H, Tveit A, (2012) Asymmetric dimethylarginine levels are highly associated with atrial fibrillation in an elderly population. Cardiol Res 3:109–115. https://doi.org/10.4021/cr175wCrossRefPubMedPubMedCentral

259.

Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O’Neill LA, Perretti M, Rossi AG, Wallace JL (2007) Resolution of inflammation: state of the art, definitions and terms. FASEB J 21:325–332. https://doi.org/10.1096/fj.06-7227revCrossRefPubMed

260.

Serhan CN, Gupta SK, Perretti M, Godson C, Brennan E, Li Y, Soehnlein O, Shimizu T, Werz O, Chiurchiu V, Azzi A, Dubourdeau M, Gupta SS, Schopohl P, Hoch M, Gjorgevikj D, Khan FM, Brauer D, Tripathi A, Cesnulevicius K, Lescheid D, Schultz M, Sarndahl E, Repsilber D, Kruse R, Sala A, Haeggstrom JZ, Levy BD, Filep JG, Wolkenhauer O (2020) The atlas of inflammation resolution (AIR). Mol Aspects Med 74:100894. https://doi.org/10.1016/j.mam.2020.100894CrossRefPubMedPubMedCentral

261.

Servatius H, Porro A, Pless SA, Schaller A, Asatryan B, Tanner H, de Marchi SF, Roten L, Seiler J, Haeberlin A, Baldinger SH, Noti F, Lam A, Fuhrer J, Moroni A, Medeiros-Domingo A (2018) Phenotypic spectrum of HCN4 mutations: a clinical case. Circ Genom Precis Med 11:e002033. https://doi.org/10.1161/CIRCGEN.117.002033CrossRefPubMed

262.

Sharma P, Barrett TW, Ng J, Knoten C, Ferreira AJ, Goldberger JJ (2017) Surface ECG f wave analysis at initial onset of paroxysmal and persistent atrial fibrillation. J Cardiovasc Electroph 28:498–503. https://doi.org/10.1111/jce.13188CrossRef

263.

Shen MJ, Arora R, Jalife J (2019) Atrial myopathy. JACC Basic Transl Sci 4:640–654. https://doi.org/10.1016/j.jacbts.2019.05.005CrossRefPubMedPubMedCentral

264.

Shih JY, Tsai WC, Huang YY, Liu YW, Lin CC, Huang YS, Tsai LM, Lin LJ (2011) Association of decreased left atrial strain and strain rate with stroke in chronic atrial fibrillation. J Am Soc Echocardiogr 24:513–519. https://doi.org/10.1016/j.echo.2011.01.016CrossRefPubMed

265.

Shoemaker MB, Shah RL, Roden DM, Perez MV (2020) How will genetics inform the clinical care of atrial fibrillation? Circ Res 127:111–127. https://doi.org/10.1161/CIRCRESAHA.120.316365CrossRefPubMedPubMedCentral

266.

Sinha AM, Diener HC, Morillo CA, Sanna T, Bernstein RA, Di Lazzaro V, Passman R, Beckers F, Brachmann J (2010) Cryptogenic stroke and underlying atrial fibrillation (CRYSTAL AF): design and rationale. Am Heart J 160(36–41):e31. https://doi.org/10.1016/j.ahj.2010.03.032CrossRef

267.

Sinner MF, Tucker NR, Lunetta KL, Ozaki K, Smith JG, Trompet S, Bis JC, Lin H, Chung MK, Nielsen JB, Lubitz SA, Krijthe BP, Magnani JW, Ye J, Gollob MH, Tsunoda T, Muller-Nurasyid M, Lichtner P, Peters A, Dolmatova E, Kubo M, Smith JD, Psaty BM, Smith NL, Jukema JW, Chasman DI, Albert CM, Ebana Y, Furukawa T, Macfarlane PW, Harris TB, Darbar D, Dorr M, Holst AG, Svendsen JH, Hofman A, Uitterlinden AG, Gudnason V, Isobe M, Malik R, Dichgans M, Rosand J, Van Wagoner DR, Consortium M, Consortium AF, Benjamin EJ, Milan DJ, Melander O, Heckbert SR, Ford I, Liu Y, Barnard J, Olesen MS, Stricker BH, Tanaka T, Kaab S, Ellinor PT (2014) Integrating genetic, transcriptional, and functional analyses to identify 5 novel genes for atrial fibrillation. Circulation 130:1225–1235. https://doi.org/10.1161/CIRCULATIONAHA.114.009892CrossRef

268.

Siontis KC, Yao X, Pirruccello JP, Philippakis AA, Noseworthy PA (2020) How will machine learning inform the clinical care of atrial fibrillation? Circ Res 127:155–169. https://doi.org/10.1161/CIRCRESAHA.120.316401CrossRefPubMed

269.

Song J, Navarro-Garcia JA, Wu J, Saljic A, Abu-Taha I, Li L, Lahiri SK, Keefe JA, Aguilar-Sanchez Y, Moore OM, Yuan Y, Wang X, Kamler M, Mitch WE, Ruiz-Hurtado G, Hu Z, Thomas SS, Dobrev D, Wehrens XH, Li N (2023) Chronic kidney disease promotes atrial fibrillation via inflammasome pathway activation. J Clin Invest. https://doi.org/10.1172/JCI167517CrossRefPubMedPubMedCentral

270.

Spurrell P, Kamalvand K, Higson M, Sulke N (2004) Temporal changes in atrial refractoriness following DC cardioversion of persistent atrial fibrillation in man. Europace 6:229–235. https://doi.org/10.1016/j.eupc.2004.01.006CrossRefPubMed

271.

Staerk L, Preis SR, Lin H, Lubitz SA, Ellinor PT, Levy D, Benjamin EJ, Trinquart L (2020) Protein biomarkers and risk of atrial fibrillation: the FHS. Circ Arrhythm Electroph 13:e007607. https://doi.org/10.1161/CIRCEP.119.007607CrossRef

272.

Stiles MK, John B, Wong CX, Kuklik P, Brooks AG, Lau DH, Dimitri H, Roberts-Thomson KC, Wilson L, De Sciscio P, Young GD, Sanders P (2009) Paroxysmal lone atrial fibrillation is associated with an abnormal atrial substrate: characterizing the “second factor.” J Am Coll Cardiol 53:1182–1191. https://doi.org/10.1016/j.jacc.2008.11.054CrossRefPubMed

273.

Thomas L, Abhayaratna WP (2017) Left atrial reverse remodeling: mechanisms, evaluation, and clinical significance. JACC Cardiovasc Imag 10:65–77. https://doi.org/10.1016/j.jcmg.2016.11.003CrossRef

274.

Thorolfsdottir RB, Sveinbjornsson G, Sulem P, Helgadottir A, Gretarsdottir S, Benonisdottir S, Magnusdottir A, Davidsson OB, Rajamani S, Roden DM, Darbar D, Pedersen TR, Sabatine MS, Jonsdottir I, Arnar DO, Thorsteinsdottir U, Gudbjartsson DF, Holm H, Stefansson K (2017) A missense variant in PLEC increases risk of atrial fibrillation. J Am Coll Cardiol 70:2157–2168. https://doi.org/10.1016/j.jacc.2017.09.005CrossRefPubMedPubMedCentral

275.

Tops LF, Delgado V, Bertini M, Marsan NA, Den Uijl DW, Trines SA, Zeppenfeld K, Holman E, Schalij MJ, Bax JJ (2011) Left atrial strain predicts reverse remodeling after catheter ablation for atrial fibrillation. J Am Coll Cardiol 57:324–331. https://doi.org/10.1016/j.jacc.2010.05.063CrossRefPubMed

276.

Triposkiadis F, Pieske B, Butler J, Parissis J, Giamouzis G, Skoularigis J, Brutsaert D, Boudoulas H (2016) Global left atrial failure in heart failure. Eur J Heart Fail 18:1307–1320. https://doi.org/10.1002/ejhf.645CrossRefPubMed

277.

Tsai PC, Liao YC, Wang YS, Lin HF, Lin RT, Juo SH (2013) Serum microRNA-21 and microRNA-221 as potential biomarkers for cerebrovascular disease. J Vasc Res 50:346–354. https://doi.org/10.1159/000351767CrossRefPubMed

278.

Tsang TS, Gersh BJ, Appleton CP, Tajik AJ, Barnes ME, Bailey KR, Oh JK, Leibson C, Montgomery SC, Seward JB (2002) Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 40:1636–1644. https://doi.org/10.1016/s0735-1097(02)02373-2CrossRefPubMed

279.

van Ouwerkerk AF, Hall AW, Kadow ZA, Lazarevic S, Reyat JS, Tucker NR, Nadadur RD, Bosada FM, Bianchi V, Ellinor PT, Fabritz L, Martin JF, de Laat W, Kirchhof P, Moskowitz IP, Christoffels VM (2020) Epigenetic and transcriptional networks underlying atrial fibrillation. Circ Res 127:34–50. https://doi.org/10.1161/CIRCRESAHA.120.316574CrossRefPubMedPubMedCentral

280.

Varghese B, Feldman DI, Chew C, Valilis E, Blumenthal RS, Sharma G, Calkins H (2021) Inflammation, atrial fibrillation, and the potential role for colchicine therapy. Heart Rhythm O2(2):298–303. https://doi.org/10.1016/j.hroo.2021.03.011CrossRef

281.

Venkatraman A, Hardas S, Patel N, Singh Bajaj N, Arora G, Arora P (2018) Galectin-3: an emerging biomarker in stroke and cerebrovascular diseases. Eur J Neurol 25:238–246. https://doi.org/10.1111/ene.13496CrossRefPubMed

282.

Venteclef N, Guglielmi V, Balse E, Gaborit B, Cotillard A, Atassi F, Amour J, Leprince P, Dutour A, Clement K, Hatem SN (2015) Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines. Eur Heart J 36:795–805a. https://doi.org/10.1093/eurheartj/eht099CrossRefPubMed

283.

Vergaro G, Aimo A, Rapezzi C, Castiglione V, Fabiani I, Pucci A, Buda G, Passino C, Lupon J, Bayes-Genis A, Emdin M, Braunwald E (2022) Atrial amyloidosis: mechanisms and clinical manifestations. Eur J Heart Fail 24:2019–2028. https://doi.org/10.1002/ejhf.2650CrossRefPubMed

284.

Voigt N, Li N, Wang Q, Wang W, Trafford AW, Abu-Taha I, Sun Q, Wieland T, Ravens U, Nattel S, Wehrens XH, Dobrev D (2012) Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+–Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. Circulation 125:2059–2070. https://doi.org/10.1161/CIRCULATIONAHA.111.067306CrossRefPubMedPubMedCentral

285.

Voskoboinik A, Kalman JM, De Silva A, Nicholls T, Costello B, Nanayakkara S, Prabhu S, Stub D, Azzopardi S, Vizi D, Wong G, Nalliah C, Sugumar H, Wong M, Kotschet E, Kaye D, Taylor AJ, Kistler PM (2020) Alcohol abstinence in drinkers with atrial fibrillation. N Engl J Med 382:20–28. https://doi.org/10.1056/NEJMoa1817591CrossRefPubMed

286.

Walker M, Patel P, Kwon O, Koene RJ, Duprez DA, Kwon Y (2022) Atrial fibrillation and hypertension: “quo vadis.” Curr Hypertens Rev 18:39–53. https://doi.org/10.2174/1573402118666220112122403CrossRefPubMed

287.

Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, Horowitz JD, Hylek EM, Lopes RD, Asberg S, Granger CB, Siegbahn A, Investigators A (2014) Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Circulation 130:1847–1858. https://doi.org/10.1161/CIRCULATIONAHA.114.011204CrossRefPubMed

288.

Wanahita N, Messerli FH, Bangalore S, Gami AS, Somers VK, Steinberg JS (2008) Atrial fibrillation and obesity–results of a meta-analysis. Am Heart J 155:310–315. https://doi.org/10.1016/j.ahj.2007.10.004CrossRefPubMed

289.

Wang GD, Shen LH, Wang L, Li HW, Zhang YC, Chen H (2009) Relationship between integrated backscatter and atrial fibrosis in patients with and without atrial fibrillation who are undergoing coronary bypass surgery. Clin Cardiol 32:E56-61. https://doi.org/10.1002/clc.20420CrossRefPubMedPubMedCentral

290.

Wang S, Jun J, Cong L, Du L, Wang C (2021) miR-328-3p, a predictor of stroke, aggravates the cerebral ischemia-reperfusion injury. Int J Gen Med 14:2367–2376. https://doi.org/10.2147/IJGM.S307392CrossRefPubMedPubMedCentral

291.

Wanishsawad C, Roongsritong C, Sitthi-Amorn C, Puavilai W (1994) Spontaneous echo contrast on transthoracic echocardiography and left atrial thrombus in rheumatic mitral valve disease patients: a clinicopathologic study. Clin Cardiol 17:547–551. https://doi.org/10.1002/clc.4960171007CrossRefPubMed

292.

Watts M, Kolluru GK, Dherange P, Pardue S, Si M, Shen X, Trosclair K, Glawe J, Al-Yafeai Z, Iqbal M, Pearson BH, Hamilton KA, Orr AW, Glasscock E, Kevil CG, Dominic P (2021) Decreased bioavailability of hydrogen sulfide links vascular endothelium and atrial remodeling in atrial fibrillation. Redox Biol 38:101817. https://doi.org/10.1016/j.redox.2020.101817CrossRefPubMed

293.

Wei Y, Liu S, Yu H, Zhang Y, Gao W, Cui M, Li L (2020) The predictive value of growth differentiation factor-15 in recurrence of atrial fibrillation after catheter ablation. Mediators Inflamm 2020:8360936. https://doi.org/10.1155/2020/8360936CrossRefPubMedPubMedCentral

294.

Weng LC, Preis SR, Hulme OL, Larson MG, Choi SH, Wang B, Trinquart L, McManus DD, Staerk L, Lin H, Lunetta KL, Ellinor PT, Benjamin EJ, Lubitz SA (2018) Genetic predisposition, clinical risk factor burden, and lifetime risk of atrial fibrillation. Circulation 137:1027–1038. https://doi.org/10.1161/CIRCULATIONAHA.117.031431CrossRefPubMed

295.

Wieberdink RG, van Schie MC, Koudstaal PJ, Hofman A, Witteman JC, de Maat MP, Leebeek FW, Breteler MM (2010) High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke 41:2151–2156. https://doi.org/10.1161/STROKEAHA.110.586289CrossRefPubMed

296.

Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA (1995) Atrial fibrillation begets atrial fibrillation. a study in awake chronically instrumented goats. Circulation 92:1954–1968. https://doi.org/10.1161/01.cir.92.7.1954CrossRefPubMed

297.

Willeit P, Freitag DF, Laukkanen JA, Chowdhury S, Gobin R, Mayr M, Di Angelantonio E, Chowdhury R (2015) Asymmetric dimethylarginine and cardiovascular risk: systematic review and meta-analysis of 22 prospective studies. J Am Heart Assoc 4:e001833. https://doi.org/10.1161/JAHA.115.001833CrossRefPubMedPubMedCentral

298.

Wolder LD, Graff C, Baadsgaard KH, Langgaard ML, Polcwiartek C, Ji-Young Lee C, Skov MW, Torp-Pedersen C, Friedman DJ, Atwater B, Overvad TF, Nielsen JB, Hansen SM, Sogaard P, Kragholm KH (2023) Electrocardiographic P terminal force in lead V1, its components, and the association with stroke and atrial fibrillation or flutter. Heart Rhythm 20:354–362. https://doi.org/10.1016/j.hrthm.2022.11.010CrossRefPubMed

299.

Wollert KC, Kempf T, Wallentin L (2017) Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clin Chem 63:140–151. https://doi.org/10.1373/clinchem.2016.255174CrossRefPubMed

300.

Wong CX, Abed HS, Molaee P, Nelson AJ, Brooks AG, Sharma G, Leong DP, Lau DH, Middeldorp ME, Roberts-Thomson KC, Wittert GA, Abhayaratna WP, Worthley SG, Sanders P (2011) Pericardial fat is associated with atrial fibrillation severity and ablation outcome. J Am Coll Cardiol 57:1745–1751. https://doi.org/10.1016/j.jacc.2010.11.045CrossRefPubMed

301.

Wozakowska-Kaplon B, Bartkowiak R, Janiszewska G (2010) A decrease in serum aldosterone level is associated with maintenance of sinus rhythm after successful cardioversion of atrial fibrillation. Pac Clin Electroph 33:561–565. https://doi.org/10.1111/j.1540-8159.2009.02673.xCrossRef

302.

Wright CB, Dong C, Stark M, Silverberg S, Rundek T, Elkind MS, Sacco RL, Mendez A, Wolf M (2014) Plasma FGF23 and the risk of stroke: the northern manhattan study (NOMAS). Neurology 82:1700–1706. https://doi.org/10.1212/WNL.0000000000000410CrossRefPubMedPubMedCentral

303.

Wu CH, Hu YF, Chou CY, Lin YJ, Chang SL, Lo LW, Tuan TC, Li CH, Chao TF, Chung FP, Liao JN, Chen SA (2013) Transforming growth factor-beta1 level and outcome after catheter ablation for nonparoxysmal atrial fibrillation. Heart Rhythm 10:10–15. https://doi.org/10.1016/j.hrthm.2012.09.016CrossRefPubMed

304.

Wu X, Liu Y, Tu D, Liu X, Niu S, Suo Y, Liu T, Li G, Liu C (2020) Role of NLRP3-inflammasome/caspase-1/galectin-3 pathway on atrial remodeling in diabetic rabbits. J Cardiovasc Transl Res 13:731–740. https://doi.org/10.1007/s12265-020-09965-8CrossRefPubMed

305.

Xi Q, Sahakian AV, Frohlich TG, Ng J, Swiryn S (2004) Relationship between pattern of occurrence of atrial fibrillation and surface electrocardiographic fibrillatory wave characteristics. Heart Rhythm 1:656–663. https://doi.org/10.1016/j.hrthm.2004.09.010CrossRefPubMed

306.

Xu Y, Xue Y, Wang Y, Feng D, Lin S, Xu L (2009) Multiple-modulation effects of oridonin on the production of proinflammatory cytokines and neurotrophic factors in LPS-activated microglia. Int Immunopharmacol 9:360–365. https://doi.org/10.1016/j.intimp.2009.01.002CrossRefPubMed

307.

Yamamoto S, Ono H, Motoyama H, Tachikawa H, Tagawa M, Akazawa K, Aizawa Y (2021) P-wave indices in Japanese patients with ischemic stroke: implication of atrial myopathy in subtype of ischemic stroke. J Electrocardiol 66:18–22. https://doi.org/10.1016/j.jelectrocard.2021.02.010CrossRefPubMed

308.

Yang Q, Qi X, Li Y (2014) The preventive effect of atorvastatin on atrial fibrillation: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 14:99. https://doi.org/10.1186/1471-2261-14-99CrossRefPubMedPubMedCentral

309.

Yang Y, Liu Q, Wu Z, Li X, Xiao Y, Tu T, Zhou S (2016) Stiff left atrial syndrome: a complication undergoing radiofrequency catheter ablation for atrial fibrillation. J Cardiovasc Electroph 27:884–889. https://doi.org/10.1111/jce.12966CrossRef

310.

Yao C, Veleva T, Scott L Jr, Cao S, Li L, Chen G, Jeyabal P, Pan X, Alsina KM, Abu-Taha ID, Ghezelbash S, Reynolds CL, Shen YH, LeMaire SA, Schmitz W, Muller FU, El-Armouche A, Tony Eissa N, Beeton C, Nattel S, Wehrens XHT, Dobrev D, Li N (2018) Enhanced cardiomyocyte nlrp3 inflammasome signaling promotes atrial fibrillation. Circulation 138:2227–2242. https://doi.org/10.1161/CIRCULATIONAHA.118.035202CrossRefPubMedPubMedCentral

311.

Yasuda R, Murata M, Roberts R, Tokuda H, Minakata Y, Suzuki K, Tsuruta H, Kimura T, Nishiyama N, Fukumoto K, Aizawa Y, Tanimoto K, Takatsuki S, Abe T, Fukuda K (2015) Left atrial strain is a powerful predictor of atrial fibrillation recurrence after catheter ablation: study of a heterogeneous population with sinus rhythm or atrial fibrillation. Eur Heart J Cardiovasc Imag 16:1008–1014. https://doi.org/10.1093/ehjci/jev028CrossRef

312.

Yu X, Li S, Zhu X, Kong Y (2022) Inhibitors of protease-activated receptor 4 (PAR4): a review of recent patents (2013–2021). Expert Opin Ther Pat 32:153–170. https://doi.org/10.1080/13543776.2022.2034786CrossRefPubMed

313.

Zahid A, Li B, Kombe AJK, Jin T, Tao J (2019) Pharmacological inhibitors of the NLRP3 inflammasome. Front Immunol 10:2538. https://doi.org/10.3389/fimmu.2019.02538CrossRefPubMedPubMedCentral

314.

Zhang M, Wang H, Bie M, Wang X, Lu K, Xiao H (2021) Caveolin-1 deficiency induces atrial fibrosis and increases susceptibility to atrial fibrillation by the STAT3 signaling pathway. J Cardiovasc Pharmacol 78:175–183. https://doi.org/10.1097/FJC.0000000000001066CrossRefPubMed

315.

Zhang Q, Yip GW, Yu CM (2008) Approaching regional left atrial function by tissue Doppler velocity and strain imaging. Europace. https://doi.org/10.1093/europace/eun237CrossRefPubMedPubMedCentral

316.

Zhang Y, Wang YT, Shan ZL, Guo HY, Guan Y, Yuan HT (2015) Role of inflammation in the initiation and maintenance of atrial fibrillation and the protective effect of atorvastatin in a goat model of aseptic pericarditis. Mol Med Rep 11:2615–2623. https://doi.org/10.3892/mmr.2014.3116CrossRefPubMed

317.

Zhao Y, Ji L, Liu J, Wu J, Wang Y, Shen S, Guo S, Jian R, Chen G, Wei X, Liao W, Kutty S, Liao Y, Bin J (2016) Intensity of left atrial spontaneous echo contrast as a correlate for stroke risk stratification in patients with nonvalvular atrial fibrillation. Sci Rep 6:27650. https://doi.org/10.1038/srep27650CrossRefPubMedPubMedCentral

318.

Zhou P, Waresi M, Zhao Y, Lin HC, Wu B, Xiong N, Li H, Huang Q, Luo X, Li J (2020) Increased serum interleukin-6 level as a predictive biomarker for atrial fibrillation: a systematic review and meta-analysis. Rev Port Cardiol 39:723–728. https://doi.org/10.1016/j.repc.2020.07.009CrossRefPubMed

319.

Zhou Q, Maleck C, von Ungern-Sternberg SNI, Neupane B, Heinzmann D, Marquardt J, Duckheim M, Scheckenbach C, Stimpfle F, Gawaz M, Schreieck J, Seizer P, Gramlich M (2018) Circulating MicroRNA-21 correlates with left atrial low-voltage areas and is associated with procedure outcome in patients undergoing atrial fibrillation ablation. Circ Arrhythm Electroph 11:e006242. https://doi.org/10.1161/CIRCEP.118.006242CrossRef

320.

Zhou W, Wang L, Zhou B, Wu L (2018) Catheter ablation of paroxysmal atrial fibrillation using high-density mapping-guided substrate modification. Pacing Clin Electrophysiol 41:1630–1634. https://doi.org/10.1111/pace.13524CrossRefPubMed

321.

Zhou X, Wang Z, Huang B, Yuan S, Sheng X, Yu L, Meng G, Wang Y, Po SS, Jiang H (2018) Regulation of the NRG1/ErbB4 pathway in the intrinsic cardiac nervous system is a potential treatment for atrial fibrillation. Front Physiol 9:1082. https://doi.org/10.3389/fphys.2018.01082CrossRefPubMedPubMedCentral

322.

Zhou YM, Li MJ, Zhou YL, Ma LL, Yi X (2015) Growth differentiation factor-15 (GDF-15), novel biomarker for assessing atrial fibrosis in patients with atrial fibrillation and rheumatic heart disease. Int J Clin Exp Med 8:21201–21207PubMedPubMedCentral

323.

Zlochiver S, Munoz V, Vikstrom KL, Taffet SM, Berenfeld O, Jalife J (2008) Electrotonic myofibroblast-to-myocyte coupling increases propensity to reentrant arrhythmias in two-dimensional cardiac monolayers. Biophys J 95:4469–4480. https://doi.org/10.1529/biophysj.108.136473CrossRefPubMedPubMedCentral

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Pathophysiology and clinical relevance of atrial myopathy

Abstract

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2024

Distinct cytoskeletal regulators of mechanical memory in cardiac fibroblasts and cardiomyocytes

Crosstalk of human coronary perivascular adipose-derived stem cells with vascular cells: role of tissue factor

Lysophosphatidic acid contributes to myocardial ischemia/reperfusion injury by activating TRPV1 in spinal cord

Statins affect human iPSC-derived cardiomyocytes by interfering with mitochondrial function and intracellular acidification